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Role of PKC-iota in Prostate Cancer 
 
Hla Y. Win 
 
ABSTRACT 
Prostate cancer is one of the leading causes of death among males in the United States.  
In this study, we hypothesized that an activated PKC-iota-dependent anti-apoptotic pathway, 
drives the cell cycle proliferation and survival of prostate cancer cells. 
We investigated the role of atypical PKC-iota (PKC-ι) in androgen- independent prostate 
DU-145 carcinoma, androgen-dependent prostate LNCaP carcinoma compared to transformed 
non-malignant prostate RWPE-1 cells.   Western blotting and immunoprecipitations demonstrated 
that PKC-ι is associated with cyclin-dependent activating kinase (CAK/Cdk7) in androgen-
dependent, RWPE-1 and LNCaP cells but not in androgen-independent DU-145 cells.  Treatment 
of prostate RWPE-1 cells with PKC-ι silencing RNA (siRNA) decreased cell proliferation, cell 
cycle accumulation at G2/M phase and decreased phosphorylation of Cdk7 and cdk2.  In addition, 
PKC-ι siRNA treatment provoked a decrease in phosphorylation of Bad and increased Bad/Bcl-xL 
heterodimerization, leading to cell apoptosis. 
In DU-145 cells, PKC-ι is anti-apoptotic and still required for cell survival.  Treatment with 
PKC-ι siRNA blocked an increase in cell number, and inhibited G1/S transition.  In addition to cell 
cycle arrest, both RWPE-1 cells and DU-145 cells underwent apoptosis via mitochondria 
dysfunction and activating apoptosis cascades such as release of cytochrome c, activation of 
caspase-7, and poly-(ADP-ribose) polymerase (PARP) cleavage. 
 Mechanistic pathways involving aPKCs in the NF-κB survival pathway were established 
using pro-inflammatory cytokine, tumor necrosis factor alpha (TNFα).  Results demonstrated that 
RWPE-1 cells and DU-145 cells are insensitive to TNFα whereas LNCaP cells are sensitive to 
TNFα treatment and undergo apoptosis.  In DU-145 cells, TNFα induced PKC-ι activation of IκB 
 xi
kinase, IKKα/β, while in RWPE-1 cells, PKC-ζ activates IKKα/β.   Both RWPE-1 and DU-145 
show degradation of IκBα allowing NF-κB/p65 translocation to the nucleus.  In LNCaP cells, the 
upstream kinase activation IKKα/β was not observed, although there have been reports that 
LNCaP cells weakly activate IKKα and have NF-κB activation.  In vivo kinase assay 
demonstrates that PKC-ι is the substrate of IKKα/β.  A putative PKC-ι inhibitor (ICA-1) inhibited 
activation of IKKα/β in vivo. 
Hence, PKC-ι is an antiapoptotic protein and this suggests that anti-PKC-ι therapy may 
be a viable option for prostate carcinoma cells. 
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Chapter 1 
Protein Kinase C  
1.0  Introduction 
 Kinases are enzymes that add phosphates to small molecules or other proteins creating 
active signaling molecules.   Activation and deactivation of kinases changes their internal 
biochemistry in response to signals from the outside.  One class of these kinases is protein 
kinase C (PKC).  PKC is a family of serine-theronine kinases that control many cellular processes 
such as proliferation, differentiation, immune response, transcriptional regulation, synaptic 
transmission, learning and memory [1, 2, 3].   Yasutomi Nishizuka and co-workers discovered 
PKC in early 1970s.  They called it protein kinase C because of activation by the Ca2+-dependent 
protease and calpain.  All PKCs enzymes are dependent on anionic phospholipids, in particular 
phosphatidylserine (PS) [4].  There are twelve members of PKC and they are divided into three 
subgroups; conventional, novel, and atypical PKCs.  Classical PKCs include, PKC-α, βΙ, βΙΙ, and 
γ.  Novel PKCs are PKC-δ, ε, η, and θ.  Atypical PKCs includes PKC-ι, ζΙ, ζΙΙ, and μ [4, 5, 6].  All 
PKCs have N-terminal regulatory domain and C-terminal catalytic domain also known as kinase 
domain (Figure 1.1, Table 1). 
 The regulatory domain of the enzyme (20-30 kDa) contains a pseudosubstrate, which 
binds to a substrates binding cavity of the catalytic protion and acts as an autoinhibitory module.  
The regulatory domain consists of C1 and C2 that have high anffinity for membrane interaction.  
Diacylglycerol (DAG) enhances PKCs to recruite to the membrane.  DAG interacts with C1 
domain enhancing PKCs enchoring to the membrane.  The kinase domain is approximately 45 
kDa, and contains serine-theronine residues that are phosphorylated for the kinase to be 
catalytically competent [4].  Calssical PKC can be activated by combination of Ca2+, diacylglycerol 
(DAG), and phospholipds [5-7].   
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1.1 PKC isoforms and their structural domains 
1.1.1 Conventional PKCs (cPKCs)  
 Conventional PKCs or classical PKCs ( ≈ 77 kDa) consists of PKC-α, βΙ, βΙΙ and γ.  They 
were first identified by Parker PJ et al  (1986) in bovine brain [8, 9].   They have a 
pseudosubstrate motif, phorbol ester binding sites (C1), and Ca2+ binding site at C2 region 
(Figure 1.2A, B) [4].  In addition, both C1 and C2 domains can interact with membrane.  The 
pseudosubstrate is a molecular switch that activates PKC isoforms.  It occupies the active site on 
the kinase domain which allows phosphorylation of key residues such as serine or threonine.  
The pseudosubstrate requires a specific regulator to remove it from the active site to allow 
substrate access.  Therefore, the pseudosubstrate is extremely proteolytically labile when PKC is 
active and resistant to proteolysis when the enzyme is inactive [10-13].   
 The regulatory C1 domain has been determined using X-ray crystallography and nuclear 
magnetic resonance spectroscopy (NMR) [14-23].  It is a membrane targeting module with 
compact α/β structural units of about 50 amino acids that tightly bind two zinc ions and DAG [14-
18].  In addtion, cPKCs have two “cystein-rich domains” (CRD) or “zinc-fingers” domains in C1 
region [20-21]. 
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Protein Kinase C Isoforms Structural Domains 
 
 
Figure 1.1 The family members of protein kinase C isoforms and their major structural domains.  
Conventional PKCs are activated by Ca2+, DAG, and PS.  Novel PKCs are activated by DAG and 
PS, while atypical PKCs are activated by lipids and calpain [4].  C1A and C1B (red) represents 
phorbol ester and phospho lipid binding sites, and calcium bind to C2 domain (yellow).  The 
kinase domain is represented in blue bar.
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The C2 domain is also a membrane targeting module which requires calcium (Ca2+) 
binding.  The C2 domain contains about 130 amino acids and it is involved in intracellular 
signaling and membrane trafficking.  Structural elucidation from both the crystal structure and 
NMR solution reveals a β-sheet-rich domain with Ca2+ binding pocket [5, 24-29].  It has also been 
shown that in the classical PKC-α isozymes, Ca2+ binding to membranes leads to a high 
specificity for PS.  The mechanisms involved in the membrane interactions with the C2 domain 
remain unclear.  Structural basis for lipids and Ca2+ cooperation in PKCs are also not well 
understood.  However, mutational studies throughout C2 domains showed that it docks to 
membrane and forms a “jaw” (Figure 1.3) and that aspartate is required for Ca2+ coordination and 
for membrane docking [30-32]. 
 The kinase domain is approximately 45 kDa and it is 40% identical to protein kinase A 
(PKA) and highly homologus to Akt kinase (protein kinase B).  Kinase activity is regulated by two 
independent mechanisms: first is the phosphorylation of PKC on serine and threonine residues, 
which make PKC catalytically competent; second is the removal of pseudosubstrate from the 
acitive site.  Regulation by phosphorylation is further discussed in section 1.2 [4, 33-34]. 
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Figure 1.2 Structural domains of C1 with phorbol ester binding site (A) and C2 domain with 
calcium binding site (B) on PKC [4]. 
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Figure 1.3 Interaction of C2 domain with lipid membrane [30]. 
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1.1.2 Novel PKC (nPKCs) 
 Following the discovery of PKC by Nishizuka, other researchers screened for nPKCs 
such as PKC-δ, ε, η, and θ ( ≈ 77-84 kDa) [35].  They are similar to classical PKCs but they are 
not activated by calcium (Ca2+).  The crystal structure of C1 domain shows the DAG binding 
pocket which facilitates membrane interaction [4, 36].  The C2 domain of novel PKCs have no 
aspartates for Ca2+ coordination compared to classical PKCs.  This accounts for failure to be 
activated by Ca2+ [39].  In addition anionic phospholipids containing phosphotidylinositol- 2-
phosphate (PIP2), phosphotidylinositol (PI), phosphatidic acid (PA), phosphotidylglycerol (PG) or 
phosphotidylserine (PS) can bind to the C2 domain replacing the requirement of Ca2+ [36].  Thus, 
DAG binding and anionic phospholids binding facilitates nPKCs translocation to the membrane 
site for subsequent activation. 
1.1.3 Atypical PKC (aPKCs) 
 Atypical PKCs include PKC-ι, ζ and μ  (protein kinase D: PKD) (≈ 67 and 115 kDa).  The 
kinase domain of aPKCs is similar to cPKCs and nPKCs. The significant differences lie in the C1 
domain.  The C1 domains of atypical PKCs do not bind DAG.  They also lack a calcium binding 
pockets.  Hence, they are not activated by DAG or Ca2+.  In addition, atypical PKCs have only 
one zinc finger domain. A recent report indicates that ceramide directly activates PKC-ζ in vitro 
[4, 37].  The catalytic regions of aPKCs are also highly homologus to those of other PKCs.
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Protein Kinase C isoforms 
 
Table 1: PKC family and their expression in tissue type.  
PKC 
isofoms 
MWt 
(kDa) 
Amino acids Predominant Tissue Expression 
Conventional PKC subfamily: 
α 76.8 671 ubiquitous, high in T cells 
βΙ, ΙΙ 76.8 672 ubiquitous, high in B cells 
γ 77.9 696 Brain 
Novel PKC subfamily: 
δ 77.5 675 T cells, B cells, platelets 
ε 83.5 736 T cells, B cells, platelets 
η 78.0 681 ubiquitous, high in T cells 
θ 81.6 705 T cells, neurons, absent in B cells 
Atypical PKC subfamily: 
ι/λ 67.2 586 ubiquitous 
ζ 67.7 591 ubiquitous 
μ 115 912 ubiquitous 
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1.2 Regulation of PKC 
1.2.1 Regulation by autophosphorylation  
 PKC activity is regulated by phosphorylation and activation by cofactors such as PS, 
DAG and Ca2+ depending on the isoforms.  Newly synthesized PKCs are inactive and their 
pseudosubstrates are away from the substrates binding cavity.  At this stage, PKC weakly 
interacts with the membrane (inactive state) [38-41].  The maturation of PKC involves a series of 
phosphorylations initiated by phospho-dependent kinase 1 (PDK-1) and other substrates.  
Phosphorylation of PKC was first observed by Fabbro and coworkers when they used 12-phorbol 
13-myristate acetate (PMA), referred to as 12-O-tetradecanoyl phorbol 13-acetate (TPA), to 
activate PKC [38]. 
Phosphorylation occurs at the activation loop, turn motif, and hydrophobic site (Figure 
1.4).  First, there is a rate limiting step, phosphorylation of threonine residue 500 on the 
“activation loop”, followed by autophosphorylation at C-terminal sites (serine and theronine at 641 
and 660, respectively).  For novel PKCs, theronine 566, 710, and serine 729 get 
autophosphorated, while in atypical PKC, theronine 410 and 560 are autophosphorylated (Figure 
1.5) [36]. 
These phosphorylation steps are necessary for PKC to be catalytically competent, for 
subcellular localization and stability [39-41].  After phosphorylation, it is released into the cytosol.  
This species is maintained in an inactive state by the bound pseudosubstrate.  In this resting 
state, PKC bounces on and off the membranes by diffusion-limited reactions.  However, its affinity 
for membrane is so low that its lifetime on the membrane is too short to be significant.  
1.2.2 Regulation by membrane interaction and anchoring protein 
 The next step in the regulation of PKC is the translocation of PKCs from cytosol to the 
membrane site.  A landmark finding in 1982 by Anderson, Sando and coworkers described that 
phorbol ester caused rapid depletion of PKC activity from cytosol, followed by redistribution of 
PKC from cytosol to membrane [42-45].  Newly synthesized PKCs weakly interact with 
membrane however anchoring proteins such as receptors for activated C kinase (RACKS) and 
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substrates that interact with C kinase (STICKS) facilitate PKC translocation to the membrane 
sites and allow interaction with cofactors [14].  Hence, anchoring proteins strongly hold PKCs to 
membrane sites.  In the presence of cofactors at the membrane sites: PS, DAG and Ca2+, the 
“inactive” PKCs are translocated to membrane.  PS and DAG can bind to the C1 domain while 
calcium (Ca2+) binds to C2 domain.  Binding of one or more ligands provide sufficient energy for 
the pseudosubstrate to be released from the active site and allow substrate binding (activated 
state) [14].   
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Figure 1.4 Alignment of activation loop, turn motif and hydrophobic sites of PKCs, Akt, PKA and S6K.  Generally PKCs are phosphorylated on 
activation loop (Threonine 500), turn motif (Theronine 641) and hydrophobic motif (serine 660) [36].  
 
Protein kinase C phosphorylation sites 
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Figure 1.5 Specific phosphorylation events of conventional, novel, and atypical PKCs [14].   
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1.2.3 Downregulation of PKC 
In addition to activation of PKC, phorbol ester is able to downregulate PKC.  
Downregulation involves decrease in phosphorylation of PKC and its enzyme activity.  Studies 
have shown that prolonged treatment with phorbol esters result in downregulation of PKC by 
dephosphorylation.  However, downregulation of PKC and their mechanisim is unsolved.  At least 
in part, phorbol ester treatment leads to chronic PKC activation, leading to proteolytic cleavage 
and downregulation of PKC.  An anchoring protein sequesters downregulated PKC, where PKC is 
rephosphorylated.  However, this theory is still under study [46-48]. 
In addition, downregulation of PKC is achieved by degradation of PKC by the proteosome 
[49, 50].  Moreover, dephosphorylated enzyme is more sensitive to phosphatases, proteases and 
oxidation leading to inactivation of PKC [49-51]. 
1.2.4 Singnificant of PKC 
 Many cancer cells utilize PKCs to activate cell proliferation and survival pathways.  
However, PKCs have not being investigated thoroughly in prostate cancer.  This study 
investigates the role of atypical PKC in cell cycle progression, apoptosis and survival pathways in 
prosate cancer.  We established three specific aims: 1) to determine whether a PKC-ι/Cdk7/cdk2 
signaling pathway contributes to prostate cancer cell cycle regulation; 2) to determine whether 
PKC-ι phosphorylation of Bad promotes prostate cancer survival by disruption of the proapoptotic 
Bad/Bcl-xL interaction; 3) to determine whether PKC-ι activates the NF-κB survival pathway in 
prostate cells.
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Chapter 2 
Prostate Cancer 
2.0 Introduction 
 The prostate is a gland found only in human.  It is about the size of a walnut, located 
below the bladder and in front of the rectum (Figure 2.1).  The function of the prostate is to add 
various components to the seminal fluid [1].  It has been estimated that in United States, 1 out of 
6 men will develop prostate cancer in his lifetime.  In 2007, prostate cancer is second only to lung 
cancer among the cancer patients [2].  Prostate cancer rarely causes symptoms until it is in an 
advanced stage.  The digital rectal examination (DRE) or serum prostate-specific antigen (PSA) 
elevations are the two recommended diagnoses for prostate cancer.  Both normal and malignant 
prostate cells secrete PSA, but when cancer is present, PSA level in the circulation often rises.  
Elevated PSA levels indicate a precancerous stage even if the tumor is too small to detect [3-4]. 
 There are a number of treatments available for prostate cancer: 1) hormonal therapy 2) 
surgery 3) radiation and chemotherapy.  There are many immortalized and malignant human 
prostatic epithelial cell lines developed for prostate study.  The three most commonly used 
carcinoma cell lines are androgen-dependent, LNCaP, and androgen-independent, PC3 and DU-
145 cells.  These three cell lines were developed in 1977-1980 and have contributed significantly 
to the understanding of prostate cancer [5-6].
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Figure 2.1 From ACS: Illustration of male reproductive system and prostate gland [2]. 
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2.1 Prostate cancer cell lines and general characteristics 
2.1.1 Androgen-dependent LNCaP cells 
 LNCaP cells are androgen sensitive human prostate carcinoma cells.  It requires 
androgen for growth and survival.  They are adherent fibroblastoid cells.  They can grow in 
aggregates and as single cell (Figure 2.2).  LNCaP cells have low anchoring potential and do not 
produce a uniform monolayer in cell culture.  The androgen receptor (AR) is expressed in LNCaP 
cells.  However, the androgen receptor contains a point mutation in the ligand-binding domain 
that results in increasing binding affinity for progesterone, estradiol and antiandrogens.  They 
compete with androgens and increased the growth rate [6-9]. 
2.1.2 Androgen-independent DU-145 cells and PC-3 cells 
 DU-145 cells and PC-3 cells are androgen-independent prostate carcinoma cells.  DU-
145 were cultured from a tumor removed from a metastatic central nervous system (CNS) lesion 
[10].  A PC-3 prostatic carcinoma cell line was established from a lumbar vertebra.  Both cell lines 
can grow as either a monolayer or as single cells.  They are androgen unresponsive and do not 
express AR.  However, other studies show presence of AR in DU-145 and PC-3 cells.  These 
contradictory results could be due to tumor cell heterogeneity and different experimental 
conditions.  It is possible that the AR is expressed in early passages and lost its expression due 
to natural selection and the androgen-independent cells became the dominant cell population [6]. 
Ras gene amplification and mutation are the two major factors that appeared to be 
related to tumor progression.  However, LNCaP, DU-145 and PC-3 cells have no Ras mutations.  
In a PC-3 drug-resistant variant, Ha-Ras amplification was observed [12-15].  Tumor suppressor 
genes such as p53 and Rb are considered important factors in etiology of many human cancers.  
Mutations in p53 gene have been reported in DU-145 and PC-3 but not detected in LNCaP cells.  
In addition, LNCaP and PC-3 cells express normal Rb protein, whereas DU1-145 cells have a 
mutated Rb gene that shows a loss of 105 nucleotides and encodes a truncated Rb protein [12, 
15]. 
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2.1.3 Transformed non-malignant RWPE-1 cells 
 RWPE-1 cells were isolated from the prostate of a Caucasian man and immortalized 
using human papiloma virus (HPV-18).  These cells have an AR receptor as well as a prostate 
specific antigen (PSA).  However, they are non-malignant and do not form tumors in nude mice 
[6].  Immortalization of normal prostate cells allows detailed investigations of many processes 
such as growth regulation, androgen responsiveness, drug efficacy, drug resistance, tumor 
progression, invasion and metastasis.  It allows different aspects of normal prostatic epithelial cell 
physiology and a reproducible source for study [6].
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Figure 2.2 Photographs of prostate cells.  Non-malignant RWPE-1 cells, androgen-dependent 
LNCaP carcinoma, androgen-independent DU-145 and PC-3 carcinoma cells.  The pictures were 
taken from ATTC web sites. 
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2.2 Prostate cell cycle and proliferation 
2.2.1 Overview of cell cycle 
 The cell cycle is the essential mechanism by which all living things reproduce.  A cell 
carries out an orderly sequence of events such as DNA synthesis (S phase), and mitosis (M 
phase).  These two phases are separated by gap phase (G1 and G2).  The G1-phase is the 
interval between the completion of M-phase and the beginning of S-phase.  The G2 phase is the 
interval between the end of S-phase and the beginning of M-phase (Figure 2.3) [16]. 
 
Figure 2.3 The cell cycle.  A typical cell cycle has four phases: S, G1,  G2, and M [1]. 
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 M phase (mitosis) is subdivided into prophase, metaphase, anaphase, and telophase 
[16]. Briefly, at prophase the replicated chromosomes condense and the mitotic spindle 
assembles outside the nucleus.  At metaphase the mitotic spindle gathers all of the chromosomes 
to the center (equator) of the spindle.  At anaphase the paired chromatids separate to form two 
daughter chromosomes.  During telophase the two sets of daughter chromosomes arrive at the 
poles of the spindle.  A new nuclear envelope reassembles around each set, completing the 
formation of two nuclei and marking the end of mitosis.  The cell cytoplasm is then divided into 
two by a contractile ring of actin and myosin, producing two daughter cells (Figure 2.4) [16-17]. 
 
 
 
Figure 2.4 Major events in mitosis (http://en.wikipedia.org/wiki/Image:Major 
_events_in_mitosis). 
 26
 The cell cycle is regulated by phosphorylation of key proteins that initiate or regulate DNA 
replication, mitosis, and cytokinesis. Phosphorylation and dephosphorylation are the common 
ways used by cells to alter the activity of a protein.  Phosphorylation reactions are controlled by a 
specific set of protein kinases, for example, cylin-dependent protein kinases (cdks).  They transfer 
a phosphate group from ATP to a particular amino acid side chain on the target protein. 
Dephosphorylation is carried out by protein phosphatases [16-17]. 
 Hence, the cell cycle is regulated by protein kinases.  At least 9 structurally related cdks 
(cdk1 through cdk9) have been identified, though not all have been clearly defined in cell cycle 
regulatory roles [17-18].  For example, cdk2 is shown to oscillate during the course of the cell 
cycle while Cdk7- activating kinase (CAK) is involved in cell cycle regulation and transcription.  In 
addition to the cell cycle, cell proliferation depends on signals from other cells.  In some cases, 
extracellular signals from growth factors bind to the cell-surface receptors and activate 
intracellular signaling pathways [17-18]. 
 In cancer cells, many biochemical pathways are altered and selected for survival.  For 
example, oncogene encodes abnormally active protein encouraging cells to proliferate, even in 
the absence of appropriate extracellular signals (Figure 2.5) [16]. 
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 Figure 2.5 Normal cell proliferation compared to unrestrained cell proliferation caused by an oncogene [16]. 
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 Many proto-oncogenes control the growth of normal cells (Table 2).  However 
overexpression or mutation of any of the proto-oncogenes could cause deregulation, uncontrolled 
cell proliferation, de-differentiation, and malignant transformation.  Ras is the first oncogene found 
to be associated with a human tumor but the cells may survive even with ras mutated genes and 
acquire many ways to bypass the dysfuntional Ras [27]. 
 
 
Table 2 Selected regulatory proteins that are the products of potential oncogenes, and their 
functions.  
Proto-oncogene Functions 
PDGF, EGF, CSF Growth factors 
Src and Raf protein kinases Cytoplasmic, tyrosine-specific and 
serine/theronine-specific protein kinases 
Ras proteins Monomeric GTP-binding proteins 
Thyroid and steroid hormone receptors Nuclear receptors 
Myc, Fos/Jun, Rel Nuclear transcription factors 
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 Besides oncogenes, there are tumor-supressor genes such as Rb and p53 in healthy 
cells.  For example, p53 monitor the integrity of the DNA molecule, when changes in the DNA are 
detected, p53 protien promotes transcription of another protein, p21.  P21 enters the cell cycle 
and shut down the G1 phase.  This allows DNA repair before it enters DNA (S) synthesis phase.  
If the repair is possible, it would reduce the progression toward cancer.  If the repair is not 
possible, p53 stimulates the cell to enter apoptosis.  In total p53 could target 150 genes to 
prevent proliferation of damage cells.  Thus, a loss of tumor-supressor gene is one of the 
characteristic properties of tumor cells [27-29]. 
 
2.3 Signal Transduction: PKC signaling in cancer cells 
 PKC is involved in survival of many cancer cells such as glioma, lung, pancreatic, 
ovarian, breast and prostate cancer [16-23].  The function of PKC in cancer is complex, primarily 
because it regulates many pathways in cellular transformation.  For example, in colon cancer, 
overexpression of PKC-βΙΙ leads to hyperproliferation and increased susceptibility to 
carcinogenesis through cycloxygenase2 (COX2) and transforming growth factor-β (TGFβ) 
signaling pathways [30-31].  Whereas PKC-βI is required for cell differentiation and 
downregulation of tumorigenesis in colorectal cancer [33].  In rat intestinal epithelial cells, PKC-
βΙΙ induces cell invasion through K-Ras, Rac1, and Mek signaling pathway.  PKC- βΙΙ also 
regulates Akt phosphorylation for glucose matabolsim, and other cellular functions.  In additon, 
PKC-α, βΙ, βΙΙ,  and δ are activated by vascular endothelial growth factor (VEGF) and they 
participate in angiogneisis [35-36]. 
Tumor promoters such as phorbol esters can induce PKC activity, reduce intracellular 
drug accumulation, and promote multidrug-resistance (MDR) breast cancer (MCF7-MDR) cells 
[37-39].  Atypical PKC-ι and classical PKC-βΙΙ have been linked to phosphorylation of CAK/Cdk7 
during cell proliferation in human glioma cells [21-22]. 
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Adding to this complexity is the fact that PKC isozymes are highly homologus and 
targeting one specific isoform is a challenge in cancer cells.  Although high homology between 
PKC isozymes complicates their specific function in cell lines, understanding the roles of PKC is 
crucial to elucidate cancer cell survival and development of therapeutic agents. 
2.3.1 Targeting PKC in prostate cancer 
Prostate cancer is a prevalent disease in the Western world [40, 41].  The most common 
treatments available are radical prostatectomy, radiation therapy, and androgen deprivation.  
However, a significant number of patients will experience cancer recurrence after the treatment.  
This is mainly due to development of androgen independence in metastasis prostate cancer [42-
43]. Several growth factors such as PKC are involved in prostate cancer.  PKC isoenzymes - 
α, β, δ, ε, γ, ι, ζ, μ, and η are expressed in both normal prostate and tumor tissues [44].  LNCaP 
cells are a widely studied model for prostate cancer.   Early studies showed that activation of 
PKC-α with TPA induced apoptosis in LNCaP cells [45].  However, androgen-independent 
prostate PC-3 and DU-145 cells are insensitive to TPA [45-47]. 
In PC-3 and DU-145 cells, epidermal growth factor (EGF) signals to PKC-α and PKC-α is 
associated with growth inhibition [48-50].  In addition, the PKC-α gene is part of chromosome 
17q, and is commonly amplified in prostate cancers [51-52].  Hence, a specific inhibitor, 
aprinocarsen, a phosphorothioate antisense oligonuclotides, has been developed to block PKC-α 
expression [53-54].  Besides classical PKC-α, novel PKC-δ overexpressed in LNCaP cells 
caused phorbol ester-induced apoptosis.  However, lack of proteolytic cleavage and caspase-3 
inactivation suggested that an allosteric activation of PKC-δ is sufficient to induce apoptosis in 
LNCaP cells [55].  In PC-3 and DU-145 cells, PKC-δ is involved in cell motility and invasion of 
prostate tumor cells [56-57].  Morever, PKC-ε along with Akt promotes matrix adhesions 
containing actin filaments and βΙ intergins in recurrent prostate cancer cells [58].  PKC-ε also 
regulates P-glycoprotein (P-gp) expression, which is responsible for drug resistance in LNCaP 
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prostate carcinoma cells [59].  In DU-145 cells the downregulation of PKC-ε prevented apoptosis 
[60].  Hence, PKC-ε is being targeted for prostate therapy. 
PKC-μ and PKC-ζ-mTOR(mammalian target of rapamycin)/p70 S6 kinase pathway is 
associated with progression of androgen-dependent prostate cancer to androgen-independent 
prostate cancer [61-63].  However, this linkage remains to be established.  Nonetheless, 
understanding PKC isoforms in prostate cancer may contribute to possible therapeutic strategies.   
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Chapter 3 
Role of PKC-ι in prostate cell cycle and proliferation 
3.0 Introduction 
 Atypical PKC-ι and PKC-ζ are structurally and functionally distinct from other PKCs [1].  
Activation of atypical PKCs is independent of DAG, Ca2+ and PS.  Their activity is regulated by 
PDK1 and through protein-protein interactions [2-9].  PKC-ζ and PKC-ι share a 72% sequence 
homology at the amino acid level [10].  However, they have distinct functions.  For example, 
overexpression of PKC-ζ leads to a longer cell doubling time, changes cell morphology, and 
increase adherence to plastic [11-12]. 
In contrast to PKC-ζ, PKC-ι is involved in carcinogenesis both in vitro and in vivo in many 
cancers [13-17].  PKC-ι and PKC-βΙΙ are linked to phosphorylation of CAK/Cdk7 during cell 
proliferation in human glioma cells [18-19].  Atypical PKCs are likely antiapoptotic proteins in 
K562 leukemia cells because overexpression of PKC-ι prevented okadaic acid (OA) and taxol-
induced apoptosis [14]. 
In non-small-cell lung cancer (NSCLC), PKC-ι phosphorylated Bad, a proapoptotic BH3-
only protein, and disrupted Bad/Bcl-xL, leading to enhanced survival and chemoresistance [20].  
In addition, PKC-ι regulates the Rac1/Pak/ Mek/Erk signaling pathway involved in cell 
proliferation of NSCLC [20-23].  In prostate cancer cells, linoleic acid (LA) and eicosapentaenoic 
acid (EPA) increased the activity of PKC-δ and PKC-ι and augmented the proliferation rate of 
LNCaP cells [5].  In addition, an increasing number of studies implicate PKC isozymes in prostate 
cancer cell regulation [24-27].  Hence, evidence is accumulating for the significant role of PKC in 
progression and metastasis of prostate cancer. 
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3.1 Materials and methods 
3.1.1 Reagents and Antibodies 
 Primary antibodies were purchased from the following companies: PKC-α (sc-8393), βΙ 
(sc-8049), δ (sc-937), ε (sc-214), γ (sc-211), θ (sc-212)   from Santa Cruz Biotechnology, CA; 
  PKC-ι (cat number 610176)  from Transduction Laboratory, Lexington, KY; PKC-ζ (catalog 
number 07-264)  from Upstate Biotechnology, Lake Placid, NY.  Secondary antibodies were 
purchased from the following companies: HRP Goat x Mouse IgG catalog number JGM035146, 
HRP Goat x Rabbit IgG catalog number JBZ035144 were from Accurate, Westbury, NY;  HRP 
Bovine anti-goat IgG (sc-2350) from Santa Cruz Biotechnology, CA; Anti-rabbit IgG HRP-linked 
antibody (catalog number 7074) from Cell Signaling Danver, MA.  Standards for PKCs are from 
various sources that came with the antibody: HeLa, Jurkat, K-562, and whole cell lysates from 
Santa Cruz Biotechnology, CA. 
All other chemicals such as HEPES (catalog number BP310-500), Tris-glycine 10X 
(catalog number BP1306), SDS (catalog number BP166-500), Tris-Base (BP152-500), Glycerol 
(catalog number BP229), Triton x100 (catalog number BP151-500), methanol (catalog number 
A407), hydrochloric acid (catalog number A144) were purchased from Fisher Scientific, Norcross, 
GA.  Ethylene glycol bis(β-aminoethyl ether)-N,N,N’,N’, -tetraacetic acid EGTA (catalog number 
E4378), sodium floride (catalog number S6521), sodium orthovanadate (catalog number S6508), 
PMSF (P7626), leupeptin (catalog number 62070), aprotinin (catalog number A6279) were 
purchased from Sigma Aldirch, St. Louis MO.  Protein assay dye (catalog number 500-0006), 
EDTA (catalog number 161-0729), Tris-Buffered Saline 10X (catalog number 170-6435) were 
purchased from Bio-Rad, Richamd, CA.  Bovine serum albumin (BSA) (catalog number 23209) 
and SuperSignal West Pico Chemiluminescent Substrate (catalog number 34080) were 
purchased from PIERCE, Rockford, IL. 
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3.1.2 Cell Culture 
RWPE-1 (CRL-11609), LNCaP (CRL-1740) and DU-145 (HTB-81) the cell lines and their 
media were obtained from American Type Tissue Culture Collection (ATCC) (Rockville, MD). 
LNCaP cells were grown in RPMI1640 (catalog number 30-2001).  DU-145 cells were grown in 
Minimum Essential Medium Eagle (MEME) earle’s balanced salt solution (catalog number 30-
2003).  LNCaP and DU-145 cells were seeded (1 x 106) and grown as a monolayer in 75 cm2 
flasks. Both RPMI1640 and MEME media were supplemented with 90% Minimum Essential 
Medium Eagle (MEME) earle’s balanced salt solution, non-essential amino acids; 1 mM sodium 
pyruvate; 2 mM L-glutamine; 1500 mg sodium bicarbonate/L; 10% fetal bovine serum (FBS) 
(catalog number 30-2020), and antibiotics 5ml (penicillin 10 U/ml and streptomycin 10 μg/ml) 
(catalog number MT-30-001-CI from Fisher Scientific) in a 5% CO2 incubator at 37 oC.  For 
RWPE-1 the media and supplements were purchased from Invitrogen, Carlsbad, CA.  RWPE-1 
cells were seeded (1 x 106) and grown as a monolayer on 75 cm2 flasks containing Keratinocyte 
Serum Free Media (catalog number 10724-011), Epidermal Growth Factor (2.5μg) (catalog 
number 10450-013) and Bovine Pituitrary Extract (25 mg) (catalog number 13028-014) and 
antibiotics 5ml (penicillin 10 U/ml and streptomycin 10 μg/ml) in a 5% CO2 incubator at 37 oC. 
3.1.3 Trypan Blue Dye Exclusion Assay 
For cell doubling time, RWPE-1 cells, LNCaP cella and DU145 cells (1x106) were seeded 
into each of five 75 cm2 flasks.  Each flask was counted every 24 hours over a 5 day period.  At 
the indicated time, cells were trypsinized, pelleted, washed with 1ml of Dulbecco’s phosphate-
buffered saline (DPBS) (catalog number 21-031-CV),  resuspended in 0.4% Trypan Blue Solution 
(catalog number T8154, Sigma), and counted using a hemacyometer.  Live (dye excluded) cells 
were counted.  The results from three separate independent experiments were used to determine 
the mean viability and standard deviation for each time point. 
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3.1.4 Cell Cycle Analysis by Flow Cytometry 
Confluent cell cultures were semi-synchronized by serum starvation for 48 hours.  Cells 
were then incubated in serum and removed at specific times, washed in DPBS, trypsinized 
(catalog number 25-053-CI, Fisher Scientific), and fixed by dropwise addition (while vortexing) of 
cold ethanol until a concentration of 60% ethanol was reached.  The day before analysis, 60% 
ethanol was decanted and PBTB (PBS, 0.2% Triton x100 and 1% bovine serum albumin) was 
added.   Triton x100 (catalog number BP151-500) and bovine serum albumin (BSA) (catalog 
number B4287) were purchased from Fisher Scientific.  The cells were counted and diluted to 
1x106 cells/ml with PBTB.  The cells were filter with cell strainer and 50 μl of RNase was added. 
Nuclei were analyzed for DNA content using a propidium iodide (PI) 10 μL staining protocol and 
flow cytometry [38].  RNase (catalog number 83931) and PI (catalog number P4170) were 
purchased from Sigma.  The distributions of 1 x 106 nuclei were quantified using a FAC STARPlus, 
flow cytometry (Becton Dickinson, San Jose, CA) and ModFitLT Cell Cycle Analysis program 
(Version 2.0; Verity Software House, Topsham, ME, USA).  The results from three separate 
independent experiments were used to determine the mean viability and standard deviation for 
each time point. 
3.1.5 Electrophoresis and Western Blotting 
 Cells (1 x 106) were placed on ice to terminate the incubation.  Cell extracts were 
prepared by washing twice with 10 ml of ice cold DPBS.  Monolayers were scraped at 4 oC, 
resuspended and sonicated in 2 ml homogenization buffer (50 mM HEPES, p.H. 7.5), 150 mM 
NaCl, 0.5% Triton-X100, 1mM EDTA, and 2mM EGTA, 0.1 mM sodium orthovanadate, 1mM 
NaF, 2mM PMSF, 2.5 μg/ml leupeptin, 1mM DTT, 0.15 U/ml aprotinin. 
Cell suspensions were centrifuged at 40 000 g for 30 min to obtain cell extracts.  Protein 
content was measured according to Bradford [40].  Protein samples were separated by 10% 
SDS-PAGE and electrophoresed 1 hour at 45-70mAmps and then transferred to nitrocellulose 
membranes by electroblotting with transfer buffer 100 ml of 10 x Tris Glycine (0.25 M Tris and 
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1.92 M glycine) and 20% methanol in 1 L of distilled water; electroblotted for one hour at 24 volts.  
For Western blot analysis with PKC antibodies, each blot was blocked for 1 hour with 5% (w/v) 
fat-free dry milk in tris-buffered saline with 0.05% Tween-20 (TTBS) solutions at room 
temperature. Protein bands were probed with primary antibody in 5% milk TTBS buffer at 4 oC 
overnight.  The primary antibodies dilutions for PKC-α, βΙ, δ, ε, γ, θ were 1:1000 (5 μg), PKC-ι and 
PKC-ζ antibodies were diluted 1:4000 (5 μg).  Membranes were subsequently washed for 15 
minutes with TTBS and 15 minutes (2x) with 3% milk TTBS.  Secondary antibodies such as 
horseradish-peroxidase-conjugate anti-mouse, anti-rabbit or anti-goat were diluted 1:10000 in 5% 
milk TTBS.  The membranes were incubated with secondary antibody at room temperature for 1 
hour.  Immunoreactive bands were visualized with SuperSignal West Pico Chemiluminescent 
Substrate: the membranes were incubated with 5 ml of Luminol enhancer and 5ml of stable 
peroxide buffer for 5 minutes and pictures were taken with Kodak flim. 
3.1.6 Statistics 
Data from three independent experiments are performed and standard error of the mean 
(S. E.M; ±) were calculated using Student’s t-test and graph using SigmaPlot 8.0TM.  P-values 
with p < 0.05 were considered significant.  Stastistical test (P) is compared between two groups 
of sample, for example, control population vs. treated population. 
 
3.2 Results 
3.2.1 Doubling Time for RWPE-1, LNCaP and DU-145 cells 
 Cell proliferation involves activation of cdks.  These proteins fluctuate throughout the cell 
cycle and are expressed in different cell cycle phases.  Like cdks, PKC isoforms may also be 
expressed transiently or constitutively in different phases of the cell cycle.  Therefore, the 
doubling time for RWPE-1, LNCaP and DU-145 cells were first established to determine if PKC-ι 
expression is transient or constitutive.  After counting cells over 5-day period, extrapolation 
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revealed that the doubling time for three cell lines was 36 hours (Figure 3.1).  In further 
experiments, we assumed this doubling time represents the length of a cell cycle. 
3.2.2 PKC-ι expression in dividing cells and arresting cells 
 To determine if PKC-ι is involved in proliferating cells, we next focused on PKC-ι 
expression in confluent cell cycle arrested cells and dividing cells in RWPE-1, LNCaP and DU-
145.  In 100% confluent cells, there was accumulation of cells at the G0/G1 cell cycle phase, but in 
dividing cells (50% confluent), the cells undergo regular cell cycle progression (Figure 3.2 and 
Table 3). The level of PKC-ι in total cell lysates (15 μg) was higher in 50% confluent cells 
compared to 100% confluent cell cycle arrested cells (Figure 3.3A).  Other PKC isoforms such as 
PKC-α, δ, ζ, βΙ, ε were expressed constitutively with no differences between dividing and arrested 
cells.  There was no caspase-7 activation in serum starved (S) and non-serum starved (NS) cells, 
indicating no cell death in temporally arrested cells.  Absorbance densitometry revealed a two-
fold increase in PKC-ι expression in proliferating cells compared to arrested cells (Figure 3.3I).  
The presence of inactivated caspase-7 indicates that cell death was not induced by serum 
starvation.  Therefore, it is likely that PKC-ι plays a role in the proliferation of rapidly dividing cells. 
3.2.3 PKC isoforms in RWPE-1, LNCaP and DU-145 cells 
 Next, we examined the PKC isozymes profiles in RWPE-1, LNCaP and DU-145 cells.  
The expression of PKCs was not always constitutive and fluctuated throughout the cell cycle 
(Figure 3.4).  Therefore, from the 36th h (doubling time), the expressions of PKC isoforms were 
monitored.  Whole cell lysate (50-150 μg) showed that there were nine PKC isozymes present in 
RWPE-1 and DU-145 cells: PKC-α, βΙ, γ, δ, ε, θ, μ, ι and ζ.  There were high levels of PKC-δ, ι,  
and ζ present constitutively throughout the cell cycle (Figure 3.2D, H, I) and low expression of 
PKC-α, βΙ, γ, ε and μ isoforms in RWPE-1 cells and DU-145 cells (Figure 3.4A-E, G, second and 
fourth column).  There were only traces of PKC-θ, and μ (150 μg of protein) in RWPE-1 (Figure 
3.4F-G, second column).  In DU-145 cells, PKC-θ expression may regulates the cell cycle (Figure 
3.4F, fourth column).  In total, there were nine PKC isoforms present in RWPE-1 cells and DU-
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145 cells.  However, in LNCaP cells, there were only seven PKC isoforms detectable.  LNCaP 
whole cell lysates (50-100 μg) showed the presence of PKC-α, βΙ, δ, ε, μ, ι and ζ (Figure 3.4A-I, 
third column).  There was no detectable level of PKC-γ and θ isozymes (150 μg of protein) (Figure 
3.4C and F, third column).  For loading control, a relatively stable cytoskeletal protein, β-actin was 
used.  In most cases regardless of experimental treatment or technical procedure, β-actin 
expression is constant.  Hence, western blot of β-actin (50 μg) verified equal loading of protein in 
each lane. 
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Figure 3.1 Doubling time for RWPE-1 cells, LNCaP cells and DU-145 cells.  One million cells 
were seeded in each flask (time zero) and grown in their respective complete media as described 
in “Materials and Methods”.  After every 24 hours, the cells were trypsinized and viable cells were 
counted using trypan blue exclusion assay using a hematocytometry at the indicated times. For 
each time point, triplicate cultures were counted and the mean value of viable cells with the SD 
was plotted.  The graphs show the doubling time of 36 hours for RWPE-1 cells, LNCaP cells and 
DU-145 cells. 
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Figure 3.2 Effect of cell density and cell cycle progression in RWPE-1 cells, LNCaP cells and 
DU-145 cells.  FACS analysis of DNA content in 100% confluent (first column) and 50% confluent 
(second column) RWPE-1 cells, LNCaP cells and DU-145 cells.  RWPE-1 cells and LNCaP cells 
are diploid while DU-145 cells are hypotripliod.  The histograms are from one representative 
experiment and illustrate DNA content for the Go/G1 peak at (first red shaded peak), DNA 
synthesis phase (S) and gap2 and mitosis (G2M, second red shaded peak).  Forty thousand 
events were collected per time point and treatment group.  The average cell cycle distribution is 
shown in Table 3. 
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Table 3  Summary of Cell Cycle Phases for RWPE-1 cells, LNCaP cells and DU-145 cells* 
Cell Type G0/G1 S G2M 
100% Confluent RWPE-1 72 + 1 23 + 1  5 + 1 
50% Confluent RWPE-1 64 + 3 33 + 3 3 + 3  
100% Confluent LNCaP 93 + 6  6 + 5 1 + 1 
50% Confluent LNCaP 68 + 1  26 + 1 5 + 1  
100% Confluent DU145 91 + 3 3 + 1  7 +  4 
50% Confluent DU145 49 + 2 41 + 1 9 + 1  
* N=3 experiments 
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Figure 3.3 Randomly selected PKC isoforms in 50% conlfluent and 100% conlfulent prostate 
cells.  Western blots of PKC isoforms (15-100 μg) (A-H) were performed as described in “Material 
and Method”.  Inactivated caspase-7 indicates cell survival in both cells. Non-starved (NS): 100% 
confluent cells; and serum starved (S): 100% confluent cells. Western blot of β-actin indicates 
equal loading of protein in each lane.  Densitometry for the mean and standard deviation of PKC-ι 
absorbance was calculated from three independent Western blots obtained from three 
independent experiments (I).  P = 0.026 (RWPE-1 cells), P = 0.023 (LNCaP cells), and P = 0.002 
(DU-145 cells).  
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Figure 3.4 PKC isoforms in RWPE-1cells, LNCaP cells and DU145 cells.  Cells were grown to 
70-80% confluent.  The growth media was removed and the cells were semi-synchronized by 
serum starvation for 48 h (T = 0).  Growth media was then added to flasks and cells were allowed 
to grow for the indicated time (3-36 h).  Flasks were collected every three hours and cells were 
lysed as described in “Materials and Methods.”  Equal amounts of protein (50-100 μg) were 
loaded on each lane and ran on 10% SDS-PAGE.  Column 1 is the standards for PKCs, column 2 
is the PKCs isozymes from RWPE-1 cells and column 3 is the PKCs isozymes in LNCaP cells 
and column 4 is the PKC isozymes from DU145 cells at the indicated time.  Only nine PKCs 
isozymes were present: PKC-α, βΙ, γ, δ, ε, θ, μ, ι and ζ for RWPE-1 cells and DU145 cells (A-I).  
Higher protein concentrations were required to detect PKC-θ and μ  (150 μg each) and only 
traces were observed in RWPE-1 cells (F-G).  Regulation of PKC-θ expression with the cell cycle 
was observed in DU-145 cells (F).  Western blots for PKC-βΙΙ and PKC-η were performed at 
higher concentrations of protein (200 μg) for each cell line but their expressions were not 
observed.  For LNCaP, there were only seven PKC isozymes present: PKC-α, βΙ, δ, ε, μ, ι and 
ζ.  PKC PKC-γ, θ, βΙΙ and η were not observed in LNCaP cells.  β-actin (J) verified that equal 
amounts of protein were loaded in each lane. 
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3.3 Discussion 
 Previous work in glioma cells has indicated that PKC-ι plays a role in cell proliferation 
and tumor development [1].  To investigate the hypothesis involving PKC-ι in cell proliferation, 
establishing the doubling time (36 hours) for all three cell lines: RWPE-1, LNCaP, and DU-145 
enable us to fully investigate the PKCs expressions in prostate cells.  Not all proteins are 
expressed constitutively, for example cdks and p53 expression dependent on cell cycle [28, 29].  
Since protein expression could be either constitutive or transient, it is crucial to arrest the cell at 
G0/G1 stage.  At G0 stage the cells are not proliferating (arrested cells).  During this time, various 
biochemical functions are carried out in accordance with the differentiated state of the cell 
involved.   Characteristically, these cells do not synthesize DNA – i.e., they do not enter S phase 
[30].  Some investigators have suggested that the resting cell is in a special biochemical 
condition, which they called “G0”.  At quiesence (G0) stage, cellular processes are dissimilar to the 
cellular processes in the growth phase (S and G2/M phase).  Others have concluded that “G0” 
state occurs because the cell is arrested at some point in G1 (post-mitotic pre-synthetic period) 
[31, 32]. 
 In any case, one or more biochemical conditions must exit which differentiate the resting 
from the growing cell.  There are many drugs available for inducing growth arrest.  For example, 
treatment with thymidine or aphidicolin halts the cell in the G1 phase [33].   Mitotic shake-off can 
be achieved with colchicine [36] and treatment with nocodazole [35] halt the cell in M phase and 
treatment with 5-fluorodeoxyuridine halts the cell in S phase.The downside is that they can have 
toxicity effects to the cells and their physiological biochemical responses are altered. 
Therefore, cells were semi-synchronized by serum starvation [36].  Serum starvation 
shows a significant arrest in both DU-145 cells and LNCaP cells.  However, in RWPE-1 cell 
growth inhibition was 10% increased in G0/G1 and 10% decreased in S phase.  This is due to a 
characteristic of the transformed non-malignant RWPE-1 cells.  Immortilized RWPE-1 cell with 
HPV-18 disrupts the regulation of cell cycle and cell death through the interaction of E6 and E7 
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gene products that destabilize p53 and abrogate the function of Rb, respectively [37].  Hence, the 
data is consistent with the disruption of both Rb and p53 in this RWPE-1 cell line. 
Although, the cells were arrested temporally, we are able to observe some changes in 
PKCs expression significant to the cell cycle arrest.  We found that PKC-ι expression was 
decreased in arrested cells compared to rapidly proliferating prostate cells.  We also randomly 
analyzed classical PKC-α, β; novel PKC-δ, ε; and atypical PKC-ζ.   Unlike PKC-ι, other PKC 
isoforms demonstrated no significant changes in their protein expression between resting cells 
and rapidly dividing cells.  Note that during serum starvation, there was no cell death as shown by 
inactivation of caspase-7 between non-serum starved and serum starved cells.   Activation of 
caspase-7 (35 kDa) i.e., degradation to subunits 20 kDa and 10 kDa is one of the biomarkers for 
cell apoptosis [38].  Apoptosis is decribed in detail in chapater 6. 
Hence, specific fluctuation of PKC-ι between arrested cells and proliferating cells 
supports our hypothesis that PKC-ι plays a role in cell proliferation.  Analysis of PKC isozyme 
profile revealed nine PKC isoforms (α, βΙ, γ, δ, ε, θ, μ, ι and ζ) in RWPE-1 cells and DU-145 cells 
throughout their cell cycle.  LNCaP cells showed only seven PKC isoforms (α, βΙ, δ, ε, μ, ι and ζ).  
PKC-βΙΙ and η were not detected in all three cell lines, even at higher concentrations of protein 
(data not shown).  Our data is in agreement with early studies of PKC isoforms 
(α, β, δ, ε, γ, ι, ζ, μ, and η) expressed in both normal prostate and tumor tissues [39].  Not all PKCs 
expressed equally in all three cell lines.  PKC-δ, ι, and ζ were consitutively present in proliferating 
cells.  However, PKC-θ in DU-145 cells fluctuates with cell cycle. 
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Chapter 4 
Involvement of cyclin-dependent kinases (cdks) in cell proliferation  
4.0 Introduction 
 As mentioned earlier in chapter 2, cell cycle consists of S phase (DNA sythesis) and M 
phase (mitosis) and G1 and G2 phases (gap junctions) [1].   Cell cycle is controlled by cdks, a 
family of serine/theronie protein kinases.  Their regulation ensures the correct timing of kinase 
activity during cell cycle.  At least eleven cdks have been identified and their protein size ranges 
form 34-40 kDa (Table 4). However, only cdk1, 2, 4 and 6 are involved directly in cell-cycle 
control [2-7].  Cdk1 and 2 participate in M phase and S phase whereas cdk4 and 6 regulates cell 
cycle in response to extracellular factors [8]. 
Cdk5 is expressed in post-mitotic cells and is required for neural differentiation.  Cdk8 
and 9 are involved in transcription [9].  However, Cdk7 is not easily identified due to its complex 
with Cdk-activating kinase (CAK).  CAK is a trimeric enzyme composed of Cdk7-cyclin H-Mat1 
(ménage a trios) which participates in phosphorylation of other cdks and is a general component 
of transcription factor, TFIIH [10].  
 Catalytic subunits of cdks do not act alone. Their ability to trigger cell cycle events 
depends on association with cyclin subunits (Figure 4.1).  Most cyclins oscillate (i.e. expression 
level changes) during cell cycle and generate cdk activity.  For example, cyclin D-cdk4/6 and 
cyclin E-cdk2 complexes phosphorylate the retinoblastoma protein (Rb) to facilitate G1? S 
transition.  Cylin A-cdk2/1 and cyclin B-cdk1 complexes are required for S-phase progression and 
the G2? M transition respectively [11-13].
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Cyclin-dependent kinases 
Table 4 Cdks and cycling partner in cell cycle 
Species Name Size  
(amino acid) 
Cyclin Partner Function 
H. sapiens Cdk1 
Cdk2 
Cdk3 
Cdk4 
Cdk5 
Cdk6 
Cdk7 
Cdk8 
Cdk9 
Cdk10 
Cdk11 
297 
298 
305 
303 
292 
326 
346 
464 
372 
283 
502 
Cyclin B 
Cyclin E, A 
? 
Cyclin D 
p35 
Cyclin D 
Cyclin H 
Cyclin C 
Cyclin K? 
? 
? 
M 
G1/S, S, possibly M 
G1? 
G1 
Neural differentiation 
G1 
CAK, transcription 
Transcription 
S? 
G2M? 
? 
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Figure 4.1 Cyclin and cdk complexes control cell cycle regulation.  The cell cycle consists of 
G0/G1, S, G2, and M phases.  The restriction (R) point is the transition point between mitogen-
dependent to mitogen-independent progression of cell cycle.  In quiescent cells, cdk-2,-4,-5 
together with cyclin D are involved with G1 phase.  While cyclin E/cdk2 complexes are involved 
with G1/S transition.  In DNA synthesis phase (S phase), cyclin A/cdk2 and cyclin B/cdc2 
complexes are expressed.  Phosphorylation of cdc-2/cyclin B allows G2/M transition. 
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4.1 Cdk in transcription and activation by phosphorylation 
 Cyclin binding alone is not enough to fully activate cdks involved in cell-cycle control.  
Complete activation of most cdks requires phosphorylation of the cdk at a conserved threonine by 
CAK.  The fully active complex can be turned off by a variety of mechanisms: Cdk inhibitory 
subunits (CKIs) inactivate some cdk-cyclin complexes, or regulatory kinases can phosphorylate 
the cdk subunit at inhibitory sites near the N terminus [14-17]. 
 In the nucleus, CAK is part of general transcription factor (TFIIH) and phosphorylates 
RNA polymerase II at C-terminal domain (CTD) (Figure 4.2).  This allows transcription to progress 
from the preinitiation stage to the initiation stage.  At mitosis, xeroderma pigmentosum disorder 
group D (XPD) degrades dissociated CAK from TFIIH, thus, removing its transcription, promoting 
CTD kinase activity and releasing the trimetric CAK to act as a cell-cycle promoter [18].   In 
proliferating cells, CAK levels are constant and the levels of the subunits are not regulated by 
transcription or selective proteolysis.  Free CAK is then able to phosphorylate cdk1, 2, 4 and 6 
[19, 20].  For example, binding of cdk2 to cyclin A induces a conformational change in the kinase 
and allows ATP to bind the substrate. 
Secondly, CAK is phosphorylated at a threonine residue (Thr160 in human cdk2) 
optimizes substrate binding affinity and align substrates for phosphoryl transfer [21-25].  In 
addition, Cdk7 autophosphorylates at threonine 170 and serine 164.  Both sites are located on 
activation loop (T-loop).  Phosphorylation of threonine 170 (Thr170) does not increase CAK 
activity but, it facilitates the interaction between Cdk7 and cyclin H [26-28].  MAT1 can substitute 
for Thr170 phosphorylation and activates Cdk7/cyclin H [29-30].  Phosphorylation of serine 164 
enhances CAK activity and increases cyclin binding affinity [31-32]. 
 
4.2 Cdk inhibition by subunits and phosphorylation 
 The activity of cdk-cyclin complexes is controlled by cdk-inhibitory subunits (CKIs).    
There are two major structural families of CKIs: Cip/Kip and Ink4.  The Cip/Kip family includes 
p21, p27, and p57, which inhibits cdk2- and cdk4/6-cyclin complexes involved in G1 and G1/S 
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control.  Members of the Ink4 family (p15, p16, p18, and p19) specifically inhibit cdk4 and cdk6-
cyclin D complexes.  These CKIs proteins are important for promoting the arrest of the cell cycle 
in G1-phase by responding to unfavorable environmenal conditions or intracellular signals such as 
DNA damage [33-34]. 
 Phosphorylation of cdks at conserved tryrosine (Tyr15) is another mechanism where cdk-
cyclin complexes are inhibited.  In eukaryotes cells, WeeI phosphorylates Tyr 15 and inactivates 
the cdk-cylin complex.  Dephosphorylation by the phosphatase cdc25 leads to reactivation.  
Hence, a change in phosphorylation is important in the timing of mitosis, G1/S and S-phase in cdk 
activation [10]. 
 There is much evidence that CAK/Cdk7 contributes significantly in cell cycle.  Our 
hypothesis states that PKC-ι phosphorylates CAK/Cdk7, which in turn phosphorylates cdk2.  The 
following experiments were carried out to investigate the proposed pathway (Figure 4.3) in 
prostate cells.
 63
DNA
P
P
P
P
P
P
RNA
Pre-initiation Initiation Elongation
RNA-Pol II
CTD
TFIIH
P-TEFb
(Cdk9/Cylin T)
Transcription
RNA
Mitotic silencing
of transcription
CAK/XPD
XPD degredation
Phosphorylation by
   CDK1/cyclin B
P
P
P
CAK
Cdk7
Mat
cyclin H
pCAK
CDK CDK/Cyclin pCDK/Cyclin
cyclin synthesis
P
P P
P
pRb
Cell Cycle
 
Figure 4.2 Schematic illustration of cdk in transcription and phosphorylation in cell cycle control 
[18]. 
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Figure 4.3 Schematic representation of cell proliferation pathway.  We hypothesized that PKC-ι 
phosphorylates Cdk7/CAK, which in turn phosphorylates cdk2, drives cell cycle and cell 
proliferation. 
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4.3 Material and Methods 
Most materials and methods used in this chapter are found in chapter 3, section 3.1.  
Materials and methods used solely in this chapter are described below. 
4.3.1 Immunoprecipitation and Western Blot Analysis 
 Cells were placed on ice to terminate the incubation.  Cell extracts were prepared by 
washing twice with ice cold DPBS.  Monolayers were scraped at 4 oC, resuspended and 
sonicated in 2 ml homogenization buffer.  Cell suspensions were centrifuged at 40 000 g for 30 
min to obtain cell extracts.  Protein content was measured according to Bradford [39]. 
Immunoprecipitation was carried out as follows:  cell lysataes (1 mg) were pre-cleared for 
30 min at 4 oC with anti-rabbit IgG-agarose beads (1:1 v/v, 10 μl) (catalog number A8914; Sigma 
Aldrich) and incubated with 5 μg of anti-cdk7 (5 μg; sc-727) rabbit polyclonal antibody for 
overnight at 4oC and then additional 1 h with anti-rabbit IgG-agarose beads (1:1 v/v, 50 μl).  
Protein samples were separated by 10% SDS-PAGE and electroblotted onto supported 
nitrocellulose paper.  Each blot was blocked for 1 h with 5% fat-free milk TTBS solutions at room 
temperature.  Protein bands were probed with their respective primary antibody (described in 
chapter 3, section 3.1).  Phospho specific antibodies were used as follow: phospho-cdk2 
(Threonine 160) (catalog number 2561; Cell Signaling Technology, Danvers, MA) 1:1000 dilution 
(5 μg) in 5% bovine serum albumin BSA;  phospho-cdk7-T170 catalog number AP3068a 
(ABGENT, San Diego, CA) 1:1000 dilution (5 μg) in 5% BSA were incubated at 4 oC overnight 
followed by horseradish-peroxidase-conjugate anti-rabbit secondary antibody. 
The negative controls were immunoprecipitated as follow: the first negative control was 
with normal rabbit IgG beads with cell lysates (1 mg); the second negative control include cell 
lysate 1 mg plus normal rabbit IgG plus 5 μg of normal rabbit serum (catalog number 12-370; 
Upsate).  All the immuoreactive bands were visualized with chemiluminescence according to the 
manufacturers’ instructions (SuperSignal West Pico Chemiluminescent Substrate; PIERCE, 
Rockford, IL). 
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4.4 Results 
4.4.1 Association of PKC-ι and Cdk7 in RWPE-1 cell proliferation 
 Cell proliferation involves activation of cdks at different cell cycle phases.  To test if PKC-ι 
is associated with Cdk7, we immunoprecipitated PKC-ι from RWPE-1 and performed Westerns 
probing for Cdk7.  There was a transient association of PKC-ι and Cdk7 at the 30 h time point 
(Figure 4.4A).  Association of cdk2 was also observed with Cdk7 (Figure 4.4B).  Whole cell 
lysates of 100 μg were used as positive control.  The two negative controls: one with molecular 
beads and another with normal rabbit serum show no reaction with anti-Cdk7 or anti-cdk2 primary 
antibodies.  Phosphorylation of Cdk7 (Threonine 170) and cdk2 (Threonine 160) were also 
observed throughout the cell cycle (Figure 4D, 4E).  Straight Western blots of cdk2 detected the 
presence of cdk2 throughout cell cycle.  Western blots of β-actin verify equal loading of samples 
in each lane.  Taken together, these results suggest that PKC-ι is transiently associated with 
Cdk7, which in turn phosphorylated cdk2 for cell proliferation of RWPE-1 cells. 
4.4.2 Association of PKC-ι and Cdk7 in LNCaP cell proliferation 
 A similar experiment was carried out LNCaP cells.  The association of PKC-ι and Cdk7 
was observed at the 33 hour time point.  Like RWPE-1, the association was transient and weak.  
We found no association of cdk2 with Cdk7 in LNCaP cells (data not shown).  Western blot of 
cdk2 reveals fluctuation of cdk2 expression with the cell cycle whereas Cdk7 expression is 
constitutive throughout the cell cycle.  Phospho-cdk2 (Threonine 160) was observed at 21-36 
hours time point which reflects the cdk2 expression time point.  Whole cell lysates were used as 
positive controls.  Negative controls include molecular beads and normal rabbit serum.  There 
were no reactions between primary antibodies and the two negative controls.  In DU-145 cells, 
there was no association of PKC-ι with Cdk7 (data not shown); nor were PKC isozymes 
α, βΙ, δ, θ, ε, γ, ζ associated with Cdk7. 
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Figure 4.4 Association of PKC-ι with Cdk7 in RWPE-1 cells. Whole cell extracts (1 mg) from each time point were immunoprecipitated 
with rabbit polyclonal anti-Cdk7 (5 μg) as described in “Materials and Methods.” Column 1 is both positive (+) and two negative controls (-
). The positive control (+) is the whole cell lysates (100 μg), the first negative control (-) contains whole cell lysates (1 mg) plus rabbit IgG 
whole molecule (50 μl of 1:1 v/v).  The second negative control contains whole cell lysate (1 mg) plus rabbit IgG whole molecule (50 μl) 
and normal rabbit IgG serum (5 μg).  Column 2 is the cell lysates taken at the indicated time point. Immunoprecipitates were separated by 
SDS-PAGE and Western blotted with anti-PKC-ι mouse monoclonal antibody.  Physical association of PKC-ι and Cdk7 were observed at 
30 hour time points (A). Immunoprecipitation with rabbit polyclonal Cdk7 (B) showed that cdk2 is also co-immunoprecipitated (C).  
Western blot of phospho-Cdk7 (p-Cdk7; T170) phospho-cdk2 (p-cdk2; T160) were also observed (D, E).  Presence of cdk2 was observed 
throughout the cell cycle (F) and β-actin (G) shows equal loading of samples in each lane. IP: immunoprecipitation, WB: Western blot.  
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Figure 4.5 Association of PKC-ι with Cdk7 in LNCaP cells. Whole cell extracts (1 mg) from each time point were immunoprecipitated with 
rabbit polyclonal anti-Cdk7 (5 μg) as described in “Materials and Methods.” Column 1 is both positive (+) and two negative controls (-). The 
positive control (+) is the whole cell lysates (100 μg), the first negative control (-) contains whole cell lysates (1 mg) plus rabbit IgG whole 
molecule (50 μl of 1:1 v/v).  The second negative control contains whole cell lysate (1 mg) plus rabbit IgG whole molecule (50 μl) and 
normal rabbit IgG serum (5 μg).  Column 2 is the cell lysates taken at the indicated time point. Immunoprecipitates were separated by 
SDS-PAGE and Western blotted with anti-PKC-ι mouse monoclonal antibody.  Physical association of PKC-ι and Cdk7 were observed at 
30 hour time points (A) Immunoprecipitation with rabbit polyclonal Cdk7 (B).  Cdk2 expression (C) is dependent on cell cycle while Cdk7 
(D) is expressed consitutively.  Phospho-cdk2 (p-cdk2; T160) were also observed parallel to cdk2 expression (E).  Beta-actin (F) shows 
equal loading of samples in each lane. IP: immunoprecipitation, WB: Western blot.  
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4.5 Discussion 
 As mentioned above cdk-activating kinase (CAK) is a master cell cycle regulator and we 
have shown that PKC-ι transiently associates with Cdk7 at the 30 hours time point in RWPE-1 
cells.  This physical association indicates that PKC-ι may contribute to cell cycle progression.   In 
addition, we found an association between Cdk7 and cdk2.  Cdk7 is known to phosphorylate 
cdk2, 4 and 6 [35, 36].  Cdk7 also phosphorylates itself on the activation segment at theronine 
170 (T170) but does not contribute to CAK activity [29-30].  We have shown the presence of 
phospho Cdk7 and phospho cdk2 through out the time points.  The results strongly indicate PKC-
ι complexes with Cdk7 which in turn phosphorylate cdk2 at threonine 160 (T160).  Whether PKC-
ι truly phosphorylate Cdk7 is still questionable.  However, previous data indicate that PKC-ι 
activates Cdk7 in glioma cells [38].  Further experiments described in later chapters will 
strengthen our hypothesis. 
Similarly, LNCaP cells show association of PKC-ι with Cdk7 at the 33 hours time point.   
It has been shown that Cdk7 is ubiquitously expressed in tumor cells and Cdk7 activity is 
invariant during cell cycle [20, 37].  Our result also shows that Cdk7 is constitutively expressed 
through out the cell cycle.  However, cdk2 expression level fluctuate thoroughout the cell cycle.   
The phosphorylation of cdk2 was similar to cdk2 expression pattern i.e, expression from 21-36 
hours time point.  Corresponding physical association of PKC-ι and Cdk7 was observed at the 33 
hours time point.  Taken together, both RWPE-1 cells and LNCaP cells demonstrate PKC-ι 
association with Cdk7, which in turn phosphorylates cdk2 and contributes to cell proliferation.  
However, in DU-145 cells, similar experiments were carried out as above but there was no 
association of PKC-ι with Cdk7 (data not shown); nor were PKC isozymes 
α, βΙ, δ, θ, ε, γ, ζ associated with Cdk7 (data not shown).  Beside Cdk7, there are other cdks, for 
example, cdk-4 and cdk-6 can drive the cell cycle.   Hence, PKC-ι is not involved with Cdk7 in cell 
cycle but the presence of PKC-ι may be required for cell survival in DU-145 cells. 
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Chapter 5 
Effects of PKC-ι silencing RNA on cell proliferation in prostate cells 
5.1 Introduction 
 Post-transcriptional gene silencing (PTGS) is the introduction of double-stranded RNA 
(dsRNA) or RNA interference (RNAi) to knock out expression of specific genes in a variety of 
organisms [1-3].  PTGS was initially observed in petunia plants by Rich Jorgensen and 
colleagues.  They introduced a pigment-producing gene to deepen the purple color of these 
flowers.  Instead of producing deep purple color, many of these flowers develop variegated or 
white.  This phenomenon was termed ‘co-suppression’ as the expression of both the introduced 
gene and the homologus endogenous gene was suppressed [4-5]. 
 Gene silencing was performed in nematode Caenorhabditis elegans by Guo and 
Kemphues [6].  They introduced antisense RNA to block the expression of the par-1 gene in order 
to assess its function.  However, both the injected antisense RNA and sense-strand disrupted 
expression of par-1 [6].  This result was puzzling until Andrew Fire and Craig Mello introduced 
dsRNA, uncoding unc-22 RNA, into the gonad of C. elegans.  A decrease in unc-22 gene 
encoding the myofilament protein produced severe twitching movements.  In addition, neither 
sense-RNA or antisense-RNA introduction to C. elegans provoked this phenotype.  Furthermore, 
injection of dsRNA into the gut of the worm caused gene silencing not only throughout the worm, 
but also in its first generation offspring [7].  This milestone discovery led them to a Noble Prize in 
2006 and RNAi has emerged as a powerful tool in molecular biology. 
 
5.2 RNAi mechanism 
 Prior to the siRNA era, approaches such as gene targeting by homologus recombination, 
ribozymes, and antisense technologies were commonly used to determine gene functions.  
However, these techniques have limitations and none can be applied universally [8].  RNAi/PTGS 
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has facilitated an efficient and inexpensive way to study gene functions.  The key process is the 
initiation step.  In the initiation step, an RNase III like enzyme Dicer (DCR) is able to digest the 
dsRNA into 21-25 neucleotides generating small interfering RNA species (siRNA) (Figure 5.1) 
[10-12].    The double-stranded siRNAs then bind to endoribonuclease-containing complexes 
known as RNA-induced silencing complexes (RISCs), unwinding in the process. The siRNA 
strands subsequently guide RISCs complex to sequence-specific, complementary mRNA 
molecules.  The siRNA-RISC complex then cleaves the mRNA in the middle of its complementary 
region leading to the silencing of the targeted gene [13-15]. 
In eukaryotic cells, particularly in mammalian cells, dsRNAs triggered nonspecific 
suppression of gene expression [16].  This hampered RNAi function of targeted gene.  However, 
if dsRNAs are shorter than 30 bp, including siRNA duplexes, they do not affect nonspecific 
responses.  Hence, synthetic siRNAs (22-25 nucleotides) were developed to prevent nonspecific 
binding.  Another intriguing feature of RNAi is amplification of siRNA.  Studies in C. elegans and 
D. melanogaster have demonstrated that synthetic siRNAs can suppress genes similar to those 
of the long dsRNAs [10, 17].  Based on these experimental analyses, siRNAs are being optimized 
to decipher the function of virtually any gene that is expressed in a cell type or pathway-specific 
manner.   
Similarly, in the following experiments, we use PKC-ι siRNA to elucidate prostate cell 
proliferation and survival pathways. 
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Figure 5.1 The mechanism of RNA interference (RNAi) [14].
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5.3 Materials and Methods 
Most materials and methods used in this chapter are found in chapter 3, section 3.1.  Materials 
and methods used solely in this chapter are described below. 
5.3.1 Inhibition of gene expression with siRNA 
 For short interference RNAs: control siRNA-A (sc-37007), PKC-ι siRNA (h2) (sc-44320), 
PKC-ζ siRNA (sc-29451), PKC-δ siRNA (sc-36253), siRNA transfection reagent (sc-29528), and 
transfection media (sc-36868) were purchased from Santa Cruz Biotechnology, CA.  RNA 
interference functions by a regulator mechanism for sequence-specific gene silencing through 
double stranded RNA (dsRNA).  Sequence specific RNA that was 19-25 nucleotides in length 
were synthesized by Santa Cruz Biotechnology against PKC-ι.  The PKC-ι siRNA is a pooled 
sequence which consists of three combined RNA sequences – mRNA locations.  The gene 
accession number for PKC-ι is NM_002740. 
PKC-ι siRNA: 663 5’-CAAGCCAAGCGUUUCAACA-3’;5’-UGUUGAAACGCUUGGCUU G-3’; 739 
5’-GGAACGAUUGGGUUGUCAU-3’, 5’-AUGACAACCCAAUCGUUUCC-3’; 
2137 5’-CCCAAUAUCUUCUCUUGUA-3’, 5’-UACAAGAGAAGAUAUUGGG; PKC-ζ siRNA: 5’-
AAGACGACACAUGUCUCUCACCCUGUCUC 5'- AUACAUUUCU ACAGC UA GC -3' antisense: 
5’-GAGACAGGGUGAGAGACAUGUGUCGUCUU 5'-GCUAGC UGUAGAAAUGUAU -3' sense; 
PKC-δ siRNA: 5'-UCAUAAAUCAGUUUCUCAC -3' antisense 5'- AUGACAAAGAAAUUCUGAC -
3' antisense, 5'-GUGAGAAACUGAUUUA UGA -3' sense 5'- GUCAGAAUUUCUUUGUCAU -3' 
sense.  Negative controls containing a scramble sequence that do not lead to the specific 
degradation of any known cellular mRNA were synthesized.  The control siRNA-A sequence is 
proprietary and the manufacuture (Santa Cruz Biotechnology) does not reveal the sequence.  
The effects of PKC-ι, PKC-ζ, PKC-δ siRNA were determined in exponentially growing RWPE-1 
cells, LNCaP cells and DU145 cells in complete media over 72 hours.  Cells were plated on 75 
cm2 at a density of 1.5 to 2.5 x 105 cells/flask. 
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 The siRNAs complexes were made according to the following procedures:  60 μl of 
siRNAs (10 μM stock solution) were combined with 60 μl of tranfection reagent and incubated at 
room temperature for 30 minutes to make the siRNA complex.  The siRNA complex was then 
added to twenty four hours post plated cells giving a final concentration of 50 nM of siRNA 
complex in complete media.   The cells were incubated with either siRNA-A, PKC-ι, PKC-ζ, PKC-
δ siRNA (50 nM for RWPE-1, 100 nM for LNCaP and 150 nM for DU145 respectively).  Following 
treatments, the cells were washed with phosphate buffered saline (PBS), trypsinized and 
resuspended in 2-3 ml of PBS. 
Cell viability was quantified using trypan blue exclusion assay (section 3.1.1) and the 
numbers of unstained cells were counted as mentioned above.  Three independent experiments 
were carried out for each treatment with controls. Cell viability was determined relative to vehicle 
control using the mean and SD for each time point.  Statistical determination by Student’s T test 
using Minitab program (Minitab Inc. State College, PA) 
5.3.2 Western blot analysis 
Briefly, after treating the cells with their respective siRNAs, protein assay was performed 
and 15 μg of protein were loaded onto 10% SDS PAGE and Western blotted as described earlier 
in section 3.1.5.  Briefly, primary antibodies were diluted in 5% milk TTBS.  The primary 
antibodies used were a PKC-ι mouse monoclonal (5 μg, 1:4000 dilutions).  PKC-δ (5 μg, 1:1000 
dilution) and PKC-ζ (5 μg, 1:4000 dilution) were rabbit polyclonal.  Beta-actin (5 μg, 1:1000 
dilutions) was a goat polyclonal.  The nitrocellulose membranes were incubated with their 
respective antibody at 40C overnight.   The next day, primary antibodies were washed with 20 ml 
of TTBS (three times) subsequently incubated with their respective secondary antibody at room 
temperature for 1 hour.  Secondary antibodies such as HRP Goat x Mouse IgG, HRP Goat x 
Rabbit IgG, bovine anti-goat IgG were diluted 1:10000 in 5% milk TTBS.  Immuoreactive bands 
were visualized with chemilluminescence as described in section 3.1.5.   
5.3.3 Cell Cycle Analysis by Flow Cytometry 
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The detailed method was previously described in chapter 3, section 3.1.4.  Briefly, cells 
were treated with siRNA complex and removed at indicated times.  The cells were washed in 
Dulbecco’s phosphate-buffered saline (DPBS), trypsinized, and fixed by dropwise addition (while 
vortexing) of cold ethanol until a concentration of 60% ethanol was reached.  The day before 
analysis, the cells were treated with 50 μl of RNase and propidium iodide (PI) 10 μL.  The 
distributions of 1 x 106 nuclei were quantified using a FAC STARPlus flow cytometry. The results 
from three separate independent experiments were used to determine the mean viability and 
standard deviation for each time point. 
 
5.4 Results 
5.4.1 Effects of PKC-ι silencing RNA on cell proliferation in RWPE-1cells, LNCaP cells and DU-
145 cells 
 To provide additional evidence that PKC-ι is required for cell proliferation in RWPE-1 
cells, PKC-ι was temporarily inhibited using PKC-ι siRNA.  After titrating PKC-ι siRNA 
concentrations from 50-100 nM, we used an optimal concentration of PKC-ι siRNA (50 nM) and 
control siRNA to suppress PKC-ι expression.  Treatment with PKC-ι siRNA (50 nM) decreased 
the number of viable cells by 87-96% after 24-72 hours (p = 0.005, 0.004, 0.001 respectively) 
compared to control cells (Figure 5.2A).  However, transfection with siRNA complex creates some 
toxicity to RWPE-1 cells.  The control viable cells were lower than the numer of original cells 
plated at 24 h time point but it was overcome over the 24 h of incubations.  Immunoblotting of 
PKC-ι expression shows no effect in control siRNA.  Immunoblotting for PKC-ι in PKC-ι siRNA 
treated RWPE-1 cells showed that expression decreased by 90-92%.  Absorbance densitometry 
(Figure 5.3A and D) shows the average of three independent PKC-ι immunoblot for both RWPE-1 
cell treatments (p = 0.013, 0.005, 0.029).  To show specificity, we immunobloted for PKC-ζ 
isoforms which is 98% identical to PKC-ι  (Figure 3A, second row). 
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 The PKC-ι siRNA effect was isospecific to the PKC-ι isozyme and did not affect the 
atypical PKC-ζ isoforms. Similaly, LNCaP cells were treated with control siRNA and PKC-ι siRNA 
(100 nM).  However, there was no significant decrease in cell number (Figure 5.2 B).  Their p 
values were p = 0.038, 0.096, 0.269 respectively.  The siRNAs concentration was not increased 
due to some toxicity to cells.  There was a slight decrease in LNCaP control cells post 24 hour 
transfection but later cells grew back between 24-72 hour.  Immunoblot of PKC-ι shows no 
significant decrease in PKC-ι compare to control siRNA (p = 0.138, 0.050, 0.560) (Figure 5.3B 
and E).  Therefore, the cells continue to proliferate.  PKC-ι siRNA did not affect PKC-ζ isoforms 
(Figure 5.3B, second row). 
In accordance with our hypothesis that PKC-ι may be antiapoptotic and required for cell 
survival in DU-145 cells.  Treatment with PKC-ι siRNA (150 nM) showed a decrease in cell 
viability by more than 80% compared to control siRNA (p = 0.002, 0.006, 0.004) (Figure 5.2C).  
Immunoblotting for PKC-ι in PKC-ι siRNA treated DU-145 cells demonstrated a decrease in PKC-
ι expression by 60-70% between 24-72 hours (Figure 5C).  The PKC-ι siRNA effect was 
isospecific to the PKC-ι isozyme and did not affect atypical PKC-ζ isoforms (Figure 5.3C, second 
row).  Absorbance densitometry (Figure 5.3F) compared the effects of PKC-ι siRNA and show 
the average of three independent PKC-ι immunoblot for DU-145 cells (p = 0.001, 0.022, 0.015).    
5.4.2 Effects of PKC-ζ and PKC-δ silencing RNAs on cell proliferation in RWPE-1 cells and DU-
145 cells 
More specifically, RWPE-1 cells treated with PKC-ζ and PKC-δ siRNAs expressed a time 
dependent decrease in their viable cells compared to control siRNA (Figure 5.4).  The respective 
protein expression in siRNA treated cells is shown in Figure 5.4B, C.  The lack of effects on PKC-
ι expression demonstrated specificity of PKC-ι, PKC-ζ and PKC-δ siRNA treatments in both cell 
lines.  PKC-ζ ( p = 0.008, 0.007, 0.019)  siRNAs resulted in greater cell death compared to PKC-δ 
siRNA (p = 0.007, 0.001, and 0.03)  treated cells in RWPE-1 cells(Figure 5.4A).  Similar results 
were obtained with DU-145 cells treated with PKC-ζ siRNA (p = 0.048, 0.012, 0.007) and PKC-δ 
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siRNA (p = 0.002, 0.006, 0.004).  Thus, PKC-ι siRNA is isospecific to PKC-ι and does not affect 
other PKC isoforms.  Suppression of atypical PKC-ι leads to greater cell deaths in both cell lines. 
5.4.3 Effects of PKC-ι siRNA on cell cycle 
 We established by flow cytometery which cell cycle phase was disrupted by treatment 
with PKC-ι siRNA.  RWPE-1 cell cycle analysis showed a 44-63% decrease in S-phase and a 
more than two-fold increase in G2/M phase compared to control siRNA throughout the time period 
(Figure 5.5A and Table 5).  Thus, PKC-ι siRNA inhibits G2/M cell cycle phase in RWPE-1.  
However, in DU-145 cells, PKC-ι siRNA increased the G0/G1 phase by 34-36%, and decreased 
the DNA synthesis (S-phase) by 41-44% throughout the time course (Figure 5.6A and Table 6).  
Hence, PKC-ι siRNA inhibited the G1/S transition in DU-145 cells.
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Figure 5.2 Effect of PKC-ι siRNA on prostate cells. RWPE-1 (A), LNCaP (B) and DU-145 (C) 
cells.  Subconfluent cells (2.5 x 105) were treated with PKC-ι siRNA (50 nM for RWPE-1, 100 nM 
for LNCaP and 150 nM for DU-145) complex from 24-72 h as described in “Materials and 
Methods.”  At the indicated time, the viable cells were counted using trypan blue exclusion assay 
and a hematocyometry.  Three independent experiments were performed and the mean of the 
viable cells and SD were plotted.  There is a decrease in cell proliferation in PKC-ι siRNA treated 
cells compared to control siRNA. Their standard values were as follow: RWPE-1 (0.005, 0.004, 
0.001); LNCaP (0.038, 0.098, 0.269); DU-145 (0.002, 0.006, 0.004).   
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Figure 5.3 Immunoblot of PKCs in siRNA treated cells.  After counting the cells (Figure 5.2), the 
same populations of treated cells were immunoblot for PKC-ι, as described in “Materials and 
Methods.”  A protein concentration of 15 μg was loaded on each lane for each time point and 
separated by SDS-PAGE and Western blotted with anti-PKC-ι mouse monoclonal or anti-PKC-ζ 
rabbit polyclonal antibody.  There was no or very little PKC-ι present in PKC-ι siRNA treated cells 
compared to control siRNA. PKC-ι siRNA has no or very little effect on PKC-ζ indicating 
specificity (A-C). Immunoblot with goat polyclonal β-actin shows that the loading of protein is 
equal in all lanes.  Densitometry on PKC-ι immunoreactivity was taken from three independent 
westerns and the mean of their absorbance and SD was plotted (D-F).  Their p values were as 
follow: RWPE-1 (p = 0.013, 0.005, 0.029); LNCaP (p = 0.138, 0.050, 0.560); DU-145 (p = 0.001, 
0.022, 0.015).   
 
 84
A                           RWPE-1
0 24 48 72
N
um
be
r o
f v
ia
bl
e 
ce
lls
 (1
x1
03
)
0
500
1000
1500
2000
2500
3000
Control siRNA
PKC-ι siRNA 
PKC-ζ siRNA
PKC-δ siRNA
DU-145 
Hours
0 24 48 72
0
500
1000
1500
2000 Control siRNA
PKC-δ siRNA
PKC-ζ siRNA
PKC-ι siRNA
 
 
 
 
 
Figure 5.4 Effects of PKC-ζ and PKC-δ siRNA treatment on RWPE-1 cells and DU-145 cells.  (A) 
Similar density of cells were plated as mentioned in Fig. 5 and treated with PKC-ζ and PKC-δ 
siRNA respectively. Three independent experiments were performed and the mean of PKC-ζ and 
PKC-δ were plotted against PKC-ι siRNA proliferation curve (Figure 5.2); along with control 
siRNA and their SD. 
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Figure 5.4 (B) In PKC-ζ treated siRNA cells, the immunoblot of PKC-ζ and PKC-ι  was performed 
according to “Materials and Methods”.  Western blot of β-actin verify that protein level (15 μg) 
were equally loaded in each lane.  The maximal effect of PKC-ζ siRNA was at 48 h and 72 h for 
RWPE-1; 24h for DU-145 cells (C) Similarly, PKC-δ siRNA treated cells were immunoblotted for 
PKC-δ and PKC-ι respectively using specific antibodies mentioned in “Material and Method”. 
Equal amount of protein (15 μg) were loaded in each lane and verified by β-actin protein content.  
The maximal effect of PKC-δ siRNA was at 24 h and 48 h for both RWPE-1 and DU-145 cells. 
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Figure 5.5 Effects of PKC-ι siRNA on the RWPE-1 cell cycle.  Cells were treated with both 
control siRNA and PKC-ι siRNA as described in “Materials and Methods”.  At the indicated time 
the cells were trypsynized and incubated with 60% ethyl alcohol: 40% DPBS overnight at -20oC. 
The day before analysis, the 1 x 106 cells/ml were counted and treated with 1ml of PBTB, 50 μl 
RNAse and 10 μl of propidium iodine (PI).  The distributions of 40,000 nuclei were quantified 
using a FAC STARPLUS, flow cytometer and ModFitLT Cell Cycle Analysis program. The 
histograms are from one representative experiment and illustrate DNA content for Go/G1 peak at 
(first red shaded peak), DNA synthesis phase (S) and gap2 and mitosis (G2M, second red shaded 
peak).  Forty thousand events were collected per time point and treatment group. The data 
represent one of the three independent experiments.  The average cell cycle distribution is shown 
in Table 5. 
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Figure 5.6 Effects of PKC-ι siRNA DU-145 cell cycle.  Cells were treated with both control siRNA 
and PKC-ι siRNA as described in “Materials and Methods”.  At indicated times the cells were 
trypsynized and incubated with 60% ethyl alcohol: 40% DPBS overnight at -20oC. The day before 
analysis, the 1 x 106 cells/ml were counted and treated with 1ml of PBTB, 50 μl RNAse and 10 μl 
of PI.  The distributions of 40,000 nuclei were quantified using a FAC STARPLUS, flow cytometer 
and ModFitLT Cell Cycle Analysis program. The histograms are from one representative 
experiment and illustrate DNA content for Go/G1 peak at (first red shaded peak), DNA synthesis 
phase (S) and gap2 and mitosis (G2M, second red shaded peak).  Forty thousand events were 
collected per time point and treatment group. The data represent one of the three independent 
experiments.  The average cell cycle distribution is shown in Table 6.
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Table 5: Summary of non-malignant prostate, RWPE-1, cell cycle phases after treatment 
with control siRNA and PKC-ι siRNA at indicated time* 
* N = 3 independent experiments  
 
 
 
 
 
 
 
 
 
Table 6: Summary of androgen-independent prostate carcinoma, DU145, cell cycle phases 
after treatment with control siRNA and PKC-ι siRNA at indicated time* 
* N = 3 independent experiments
G0/G1 S G2/M Time (h) 
Control siRNA Control siRNA Control siRNA 
24 59 +/- 1 63 +/- 1 32 +/- 1 18 +/- 1 8 +/- 1 20 +/- 1 
48 56 +/- 1 70 +/- 1 36 +/- 1 13 +/- 1 15 +/- 4 18 +/- 2 
72 59 +/- 2 67 +/- 1 32 +/- 2 12 +/- 1 9+/- 1 22 +/- 2 
G0/G1 S G2/M Time (h) 
Control siRNA Control siRNA Control siRNA 
24 45 +/- 1 61 +/- 1 41 +/- 2 23 +/- 4 14 +/- 3 16 +/- 3 
48 47 +/- 2 63 +/- 5 39 +/- 5 23 +/- 7 14 +/- 4 15 +/- 2 
72 54 +/- 3 57 +/- 5 33 +/- 5 25 +/- 6 13 +/- 3 17 +/- 2 
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5.5 Discussion 
 To further demonstrate that PKC-ι is involved in cell proliferation, we treated the cells with 
PKC-ι siRNA to temporarily suppress PKC-ι expression.  To our knowledge, signal transduction 
pathway involving PKC-ι has not been investigated in prostate cancer cells.  Hence, this novel 
investigation will shed some light on the role of PKC-ι in prostate cancer cells.  First, we treated 
RWPE-1 cells with control siRNA (50 nM) and PKC-ι siRNA (50 nM) complex for 24-72 hour.  
The lack of proliferation demonstrated that the the transfection reagent had some toxicity toward 
RWPE-1 cells.  However, this was overcomed after 24 hour of incubation with the siRNA 
complex.  The control cells continued to proliferate while cell viability decreases in PKC-ι siRNA 
treated cells.   Western blot analysis and absorbance densitometry of PKC-ι showed a significant 
decrease in PKC-ι expression in RWPE-1 cells.  In addition, temporal suppression of PKC-ι does 
not affect PKC-ζ isoforms, which is 98% identical to PKC-ι [18]. 
 Similarly, PKC-ι was temporarily suppressed in LNCaP cells by PKC-ι siRNA.  Higher 
concentration of PKC-ι siRNA (100nM), two-fold more than RWPE-1, was used for LNCaP cells.  
However, at this concentration, PKC-ι was not significantly suppressed.  Higher concentration of 
PKC-ι siRNA was tested but this caused high toxicity to the LNCaP cells which resulted in a 
decrease in control cells as well (data not shown).  Therefore, only 100 nM of PKC-ι siRNA was 
used for LNCaP cells. 
Immunoblot analysis depicted a very slight decrease in PKC-ι expression following 24 
hour and 48 hour treatments.  Both proliferation curves and absorbance densitometry of PKC-ι 
showed no significant decrease.  However transfection of PKC-ι siRNA was specific to PKC-ι and 
did not affect PKC-ζ isoforms.  Taken together, PKC-ι may not play a significant role in 
proliferation and survival of LNCaP cells. 
There are other PKC isoforms such as PKC-α and PKC-δ play a role in LNCaP cell 
survival.  Early studies showed that activation of PKC-α and δ with TPA induced apoptosis in 
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LNCaP cells. However, the lack of proteolytic cleavage and caspase-3 inactivation suggested that 
an allosteric activation of PKC-δ is sufficient to induce apoptosis in LNCaP cells [19-22]. 
LNCaP cells are androgen sensitive and they can respond to androgen receptor 
elements (ARE) such as synthetic androgen R1881 to activate Ras-Mek-ERK signaling cascades 
for gene transcription and DNA synthesis [23].   Other possible survival pathways may involve 
activation of mitogen-activated protein kinases (MAPKs) in LNCaP cells [24-25]. 
MAPK has at least three families: extracellular signal regulated protein kinase (ERK), the 
p38 kinase, and Jun N-termianl-kinase (JNK).  Phosphorylation of ERK increases cell 
proliferation, while the p38 family is involved in apoptosis [25-30].  JNK proteins are involved in 
both positive and negative regulation of the cell cycle [31-33].  In addition, the androgen receptor 
(AR) also influences progression of LNCaP prostate cancer.  Stress kinase can regulate 
androgen receptor phosphorylation at serine 650 which is necessary for transcription and nuclear 
export.  A link between activation of MAP kinase and increased phosphorylation of serine 650 
leads to LNCaP cell survival [34].   Therefore, survival of LNCaP cells may involve other signal 
transduction pathway besides PKCs. 
 In previous investigations (chapter 3), we did not find any association of PKC-ι and 
CAK/Cdk7 in DU-145 cells.  Although PKC-ι may not be involved in cell proliferation, it may 
require for DU-145 cell survival.  Therefore, we further examined if PKC-ι siRNA would have any 
effects on DU-145 cells.  We had to use three-fold (150 nM) more of PKC-ι siRNA to suppress at 
least 50% of PKC-ι expression in DU-145 cells compared to RWPE-1 cells (50nM).    The 
proliferation curve demonstrated that the control cells continue to proliferate while PKC-ι siRNA 
treated cells were inhibited in cell number.  Western blot analysis and absorbance densitometry 
of PKC-ι showed a significant decrease in PKC-ι expression in DU-145 cells in time dependent 
manner.  In addition, temporal suppression of PKC-ι does not affect PKC-ζ isoforms. 
For specificity, we suppressed PKC-ζ and PKC-δ expression using PKC-ζ siRNA and 
PKC-δ siRNA respectively.  Their concentrations were the same as PKC-ι siRNAs, 50 nM for 
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RWPE-1 cells and 150 nM for DU-145 cells.  Both RWPE-1 cells and DU-145 cells showed a 
significant decrease in cell proliferation when treated with PKC-ζ siRNA. 
PKC-δ siRNA shows a slight decrease in cell proliferation in both cell lines.  However, 
there were more viable cells in PKC-δ siRNA treated cells compared to atypical PKC-ι and PKC-ζ 
siRNAs treated cells.  Therefore, temporarily silencing PKC-ι resulted in the slowest cell 
proliferation rate.  Immunoblot of PKC-ζ and PKC-δ show a time dependent decrease in their 
protein levels within respective cell lines.  There was no change in PKC-ι expression in PKC-ζ 
and PKC-δ siRNA treated cells.  This demonstrates that siRNAs are specific to each isozyme and 
do not effect other PKC isoforms. 
 Next, we also found that PKC-ι siRNA leads to cell cycle arrest in both cell lines.  In 
RWPE-1, PKC-ι siRNA treatment leads to G2/M arrest while in DU-145 cells, PKC-ι siRNA 
prevents G1/S transition.  In summary, suppressing PKC-ι leads to reduced cell proliferation, and 
cell cycle arrest in prostate cells.
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Chapter 6 
Cell apoptosis 
6.0 Introduction 
 In previous chapter, we have demonstrated a decrease in prostate cell viability after 
PKC-ι siRNA treatment.  It is possible that suppression of PKC-ι can lead to cell death.  Two 
alternative modes of cell death can be distinguished: apoptosis and necrosis [1].  The term 
necrosis comes from the Greek word meaning “the dead”.  This involves massive destruction of 
well integrated but, different populations of cells.  The mechanism involves inflammation and 
wound healing [2].   Apoptosis (i.e. falling autumn leaves from the Greek word) is often refer to as 
“programmed cell death” and does not involve inflammation and multicellular healing process [2].  
Programmed cell death involves activation of many regulatory pathways, preservation, 
modulating transcriptional and translational activities [1, 2]. 
 Apoptosis and necrosis have two distinct, mutually exclusive, modes of cell death.  
Apoptosis is active and executes its own demise and subsequent body disposal [3-5].  When 
apoptosis occurs in vivo apoptotic bodies are phagocytized by neighboring cells, including those 
of epithelial or fibroblast origin, without triggering an inflammatory reaction in the tissue [6-8]. 
 Both of them have distinct biochemical markers and a unique morphological appearance.  
Apoptosis involves cell shrinkage, chromatin condensation, and formation of apoptotic bodies but 
the cell membrane is preserved.  Necrosis involves swelling of cell and mitochondria followed by 
rupturing of cell membrane (Figure 6.1) [1, 2].
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Figure 6.1 Scheme illustrating morphological changes during apoptosis and necrosis [1].
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6.1 Apoptosis  
Apoptosis manifests two major pathways, the extrinsic and intrinsic pathways [9-10]. The 
molecular execution of cell death involves activation of members of a family of cysteine-
dependent aspartate-specific proteases (caspases).  The ‘intrinsic’ pathway, signals the release 
of prodeath factors form the mitochondria via the action of pro-apoptotic members of the Bcl-2 
family [11-13].  The ‘extrinsic’ pathway involves activating caspases by engagement of cell-
surface ‘death receptors’ by their specific ligands [14]. 
6.1.1 Death receptors 
Death receptors are cell-surface receptors that trigger death signals following 
engagement with their cognate ‘death ligands’ [14].  Death receptors belong to the tumor necrosis 
factor receptor (TNFR) gene super family.  They are composed of cysteien-rich domain (CRDs) in 
their amino terminal region and ‘death domain’ (DD) inserted into cytoplasm [15].  The best 
characterized death recptors are TNFR1, CD95 (also called Fas or Apo1), TRAIL-R1 (TNF-
related apoptosis-inducing ligand) [15-17].  These receptors are activated by TNF and 
lymphotoxin α.  Ligand induced trimerization of death receptors facilitates binding of adapter 
protein, FADD (Fas-associated DD protein), which interacts with death effector domain (DED) in 
caspase-8 and -10 [18-19].  This interaction allows inactivated caspase-8, -10 (procaspase) to be 
cleaved between p20 and p10 domains (activation) (Figure 6.2) [20]. 
Activation of caspase-8 further activates downstream effector caspase-3, which in turn 
cleaves other caspases (such as caspase-6) and other substrates, leading to the terminal events 
of apoptosis [21].  In addition, caspase-8 can cleave and activate BID, a “BH-3 domain only’ 
prodeath member of the Bcl-2 family [22-26]. 
The active truncated form of BID (tBID) then translocates to outer mitochondrial 
membrane, where it binds to BAX or BAK [27-28].  The tBID-induced homologomerization of BAX 
or BAK leads to mitochondrial disruption and release of prodeath cofactors (such as cytochrome 
c and Smac/DIABLO) into the cytoplasm [29].  Cytochrome c binds to procaspase-9, which 
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activates further downstream caspases such as caspase-3 and caspase-7, thereby, amplifying 
the caspase cascade and promoting apoptosis [30]. 
6.1.2 Involvement of Bcl-2 family members in apoptosis  
Apoptosis involving Bcl-2 family members (Figure 6.3) is yet another singal transduction 
cascades that targets various intracellular membranes, mitochondrial residence, pores-formation 
activity, and existence of different conformational states that contributes to programmed cell 
death.  The Bcl-2 family of proteins includes both pro- as well as anti-apoptotic molecules (Figure 
6.3).  The ratio between two subsets determines whether the cell lives or dies [31-32].  An 
additional characteristic of the members of this family is their frequent ability to form homo-as well 
as heterodimers, suggesting neutralizing competition between these proteins.  They can also 
become integral membrane proteins [31]. 
The Bcl-2 family members possess four conserved (BH) domains.  They are BH1, BH2, 
BH3 and BH4, which correspond to α-helical segments [33, 34]. Antiapoptotic members such as 
Bcl-2, Bcl-xL, and Bcl-w display all four domains while pro-apoptotic molecules such as Bax, Bak, 
MTD, and Bcl-xs display less sequence domain.  In addition, deletion and mutagenesis studies 
showed that the BH3 domain serves as a critical death domain in pro-apoptoic members. The 
subset of pro-apoptotic members “BH3-domain-only” such as Bid, Bad, and Bik are considered all 
pro-apoptotic [35-36]. 
 
6.2 Post-translational modifications determine active/inactive conformations  
Pro-apoptotic molecule Bax is monomeric and mainly resides in cytosol or loosely 
attached to membranes.  Following a death stimulus, cytosolic Bax translocates to the 
mitochondria where it becomes an integral membrane protein and cross links to form a 
homodimer.  This results in killing of cells despite the presence of survival factors and Bcl-xL [37-
38].  Like Bax, BH3-domain-only molecule, Bim can transolocate to the mitochondria following 
apoptotic stimuli.  Bim interact with Bcl-2 to antagonize its anti-apoptotic activity [39]. 
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In the presence of a survival factor, the BH3-domain-only molecule Bad is 
phosphorylated on two serine sites (ser-112 and ser-136) and is sequestered in the cytosol by 
14-3-3 molecule, a regulatory protein that interact with Bad to quench the apoptotic pathway [40].  
However, in the presence of death signals (e.g., IL-3 deprivation), Bad is dephosphorylated and 
found in association with Bcl-xL-Bcl-2, quenching its pro-apoptotic function [41]. 
To date, several kinases have been shown to phosphorylate and inactivate Bad.  
Akt/PKB/RAC phosphorylates ser-136 while PKA phosphorylates ser-112 on Bad [42-43].  
Therefore, post-translational modifications of Bcl-2 family members represent a balance between 
anti-apoptotic and pro-apoptotic and, thus, determine if the cells lives or die. 
 
6.3 Other apoptosis signals 
  Cytochorme c is a member of electron transport chain and is a soluble mitochondrial 
matrix protein.  When it is released into the cytosol, it becomes part of the machinery that causes 
cell death.  A nuclear gene encodes cytochrome c and after transcription and translation, the 
protein appears in the cytosol in the form of an apoprotein.  The later is transported to the 
mitochondrial inner membrane where a heme ligase binds the apoprotein to heme.  The 
holoenzyme is localized in the inner membrane where it is safely secured to be released only 
when the membrane barrier becomes dysfunctional [2, 44]. 
One mechanism by which cytochrome c is released is by the regulation of the Bcl-2 
family member homo and heterodimerizations inducing mitochondria dysfunction.  In addition, 
translocation of the pro-apoptotic family member (e.g., Bax) from cytosol to membrane disrupts 
the mitochondria integrity [45, 24]. 
Survivin is expressed in live cells compared to cells undergoing apoptosis.  It is a 
bifuncitonal protein that suppresses apoptosis and regulates cell division [46].  In mitosis, 
expression of survivin persists during the entire process starting at the beginning of prophase and 
disappearing at the end of telophase. 
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Survivin is associated with the microtubules of the mitotic spindles.  Thus, suvivin is 
expressed during mitosis in a cell cycle-dependent manner [46-48].  Poly (ADP-ribose) 
polymerase (PARP) is another protein marker for apoptosis.  It is a nuclear zinc-finger DNA-
binding protein that detects DNA strand breaks.  PARP is cleaved by caspases during apoptosis.  
PARP is cleaved at conserved sequence 211DEVD214 to an 89-kDa fragment containing the active 
site and an automodification domain, and to a 24 kDa fragment containing the zinc fingers, 
responsible for its DNA binding activity.  PARP cleavage has been shown in all forms of 
apoptosis, including apoptosis induced by irradiation, by chemotherapeutic agents, and upon 
activation of the death receptors [49]. 
 In this chapter, we further demonstrate that transiently silencing PKC-ι using PKC-ι 
siRNA in prostate cells leads to apoptosis.
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Figure 6.2 Model of apoptotic and survival signaling pathways involving the Bcl-2 members [20]. 
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Figure 6.3 Summary of anti-apoptotic and pro-apoptotic Bcl-2 members.  BH1-4 is Bcl-2 
homology regions while TM is the carboxy terminal hydrophobic domain [31].
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6.4 Materials and Methods 
Most materials and methods used in this chapter are found in chapter 3, sections 3.1 and 
chapter 5, section 5.3. Materials and methods used solely in this chapter are described below. 
6.4.1 Inhibition of gene expression with siRNA 
Detailed transfection was described in chapter 5, section 5.3.  Briefly, cells (3.75 x 103) 
were grown overnight in T75 flask.  Triplicate flasks were used for both control and PKC-ι 
siRNAs. The next day the control complex and PKC-ι complex (50 nM for RWPE-1 cells and 150 
nM for DU-145 cells) were added to media and incubated for 24 hours.  The flasks were then put 
on ice to terminate the incubation. 
6.4.2 Anitibodies  
Specific antibodies were purchased from Santa Cruz Biotechnology and the amount of 
antibodies used was as follow: full PARP sc-7150 (5 μg, 1:1000 dilution) rabbit polyclonal 
antibody, caspase-7 sc-8510 (5 μg, 1:1000 dilution) goat polyclonal, survivn sc-17779 (5 μg, 
1:1000 dilution) mouse monoclonal, cytochrome C sc-13560 ( 5 μg, 1:1000 dilution) mouse 
monoclonal, β-actin sc-1616 (5 μg, 1:1000 dilution) goat polyclonal, phospho-Bad (5 μg, 1:10000 
dilution) ser-112, ser-136, ser-155 (sc-7998-R, sc-12970-R, sc-7999-R respectively). 
Cleaved PARP (Asp214) (catalog number 9541) rabbit polyclonal (5 μg, 1:1000 dilutions) 
was purchased form Cell Signaling.  Secondary antibody Goat x Mouse IgG (catalog number 
JGM035146; 1 μg, 1:10000 dilution) was from Accurate.  Goat anti-rabbit sc-2004 (1 μg, 1:5000 
dilutions) was from Santa Cruz.  Anti-rabbit IgG (catalog number 7074; 1 μg, 1:1 000 dilution) was 
purchased form Cell Signaling. 
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6.4.3 Immunoprecipitation and Western blotting  
Whole cell lysates of 200 μg was immunoprecipitated with Bad mouse monoclonal 
agarose conjugate (sc-8044 AC; 5 μg).  Negative control: mouse agarose conjugate (sc-2343; 5 
μg).  The immunoprecipitated samples were run on 10% gel SDS-Page.  Western blot were 
performed using specific antibodies.  To detect phospho protein, the nitrocellulose membrane 
was blocked with 1% bovine serum albumin (BSA:milk; 1:1 v/v) containing 50 nM of NaF at room 
temperature for 1 hour.  Phospho specific primary antibodies were diluted in 20 ml of 1% 
BSA:Milk (1:1 v/v) containing 50 nM of NaF and blotted at 4 oC for overnight.  The next day, the 
primary antibody was washed three times with 20 ml of TTBS and incubated with their respective 
secondary antibody diluted in 20 ml of 1% BSA:Milk (1:1 v/v) containing 50 nM of NaF and gently 
rocked for 1 hour at room temperature.  The protein bands were visualized according to methods 
describe in chapter 3, section 3.1.5. 
 Ten percent gel SDS-PAGE was used for separation of Full PARP and cleaved PARP.  
Fifteen percent gel SDS PAGE was used to separate survivin and Cytochrome C.  All the 
membranes were probed independently and from independent experiments.  The data presented 
were the best out of triplicate experiments. 
 
6.5 Results 
6.5.1 Treatment with PKC-ι siRNAs to RWPE-1 cells and DU-145 cells leads to DNA damage 
 Previously, we have shown that PKC-ι siRNA inhibits cell cycle phase in RWPE-1 and 
DU-145 cells.  The cells were also observed under phase contrast microscopy.  The cells treated 
with PKC-ι siRNA depicted cell rounding, cell membrane blebbing, chromatin condensation and 
lifting of cells from the flask, indicating cell death compared to control cells (Figure 6.4). 
After transfecting the cells with control siRNA or PKC-ι siRNA, 15 μg of whole cell lysates 
were run on 15% SDS PAGE and analyzed for full PARP.  Full PARP rabbit polyclonal antibody 
detected full PARP 113 kDa and activation of PARP (i.e cleaved PARP) at 89 kDa.  RWPE-1 
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cells showed no significant changes in full PARP.  In contrast, there was activation of PARP 89 
kDa protein at 24 h siRNA treated cells and more significantly at the 48 h time point of siRNA 
treated cells (Figure 6.5A).  However, no significant changes occured at 72 h time point.  
Similarly, control DU-145 cells shows no changes in full PARP protein level but there was 
significant activation of PARP at 24-72 h in siRNA treated cells compared to control siRNA 
(Figure 6.5B).  Hence, activation of PARP confirmed that there is DNA damage, indicating 
apoptosis in RWPE-1 and DU-145 cells. 
 One hundred micrograms of whole cell lysates of control siRNA and PKC-ι siRNA treated 
cells were separated using 10% SDS PAGE and Western blotted with rabbit polyclonal cleaved 
PARP (Asp214) antibody.  PKC-ι siRNA treated RWPE-1 cells showed time dependent cleaved 
PARP at 89 kDa at the 24-48 h time point.  In PKC-ι siRNA treated DU-145 cells, cleaved PARP 
was observed at 24-72 h.  This indicates that all the siRNA treated cells undergo apoptosis. 
6.5.2 PKC-ι siRNAs treatment activates apoptosis cascades in RWPE-1 and DU-145 cells. 
 Next, we showed that PKC-ι siRNA treatment provokes ‘intrinsic’ apoptosis.   Fifteen 
microgram of whole cells lystates from both control and PKC-ι siRNA treated cells were run on 
15% SDS-PAGE and Western blotted for cytochorme c.  The increase in cytochrome c was 
observed in all the PKC-ι siRNA treated RWPE-1 cells and DU-145 cells (Figure 6.5).  To 
demonstrate activation of caspases during apoptosis, whole cell lysate (100 μg) of PKC-ι siRNA 
treated cells together with control cells were Western blotted for caspase-7.  In RWPE-1, a 
decrease in pro-caspase-7 was observed at 24-72 h of PKC-ι siRNA treated cells.  In contrast, 
the control siRNA treated cells showed the presence of pro-caspase-7 protein.  However, in DU-
145 PKC-ι siRNA treated cells a decrease in pro-caspase-7 was observed in time dependent 
manner at the 42 h and 72 h time points (Figure 6.5B). 
 In addition, we also Western blotted for suvivin protein (15 μg) in both cell lines after 
treatment with PKC-ι siRNA.  There was a higher level of survivn in control cells compared to 
PKC-ι siRNA treated cells.  Western blot of β-actin verified that protein loading for each sample 
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was equal.  All the Western blots were taken from the best of three independent experiments 
(Figure 6.5). 
6.5.3 Effects of PKC-ι siRNA on LNCaP cells  
 Similarly, LNCaP cells were analyzed for apoptosis although there was no significant 
reduction in cell proliferaiotion (Figure 6.6).  Whole cell lysate of 15 μg was used to analyze for 
Full PARP and cleaved PARP.  PKC-ι siRNA treated cells showed an activation of PARP (i.e. 
cleave PARP) at 24 h and 48 h time points.  However, caspase-7 activation was not observed in 
both control and PKC-ι siRNA treated cells.  In addition, there was no significant change in 
cytochorome c expression.  However, a decrease in survivin was observed at 24 h and 48 h in 
PKC-ι siRNA treated cells. 
6.5.4 Effects of PKC-ι siRNA on RWPE-1 Cdk7 and cdk2 
 Previously we have shown the association between PKC-ι and Cdk-7 in   RWPE-1 cells.  
We next determined if treatment of PKC-ι siRNA impaired the cell proliferation pathway (PKC-ι ? 
Cdk7 ? cdk2).  The cells were incubated with PKC-ι siRNA complex for 48 h and 15 μg of whole 
cell lysates were Western blotted for PKC-ι, Cdk7 and cdk2.  There was a significant decrease in 
PKC-ι expression in PKC-ι siRNA treated cells compared to control siRNA tread cells (Figure 
6.7).  There was no change in Cdk7 and cdk2 expression.  One hundred and fifty micrograms of 
whole cell lysate was used for Western blotting of phosphorylation of Cdk7 and cdk2.  We found 
that there was a significant changes in phosphorylation of Cdk7 (Th170) and cdk2 (Th160) in 
PKC-ι siRNA treated cells compared to control siRNA.  Western blot of β-actin verified equal 
loading of protein in each sample. 
6.5.5 PKC-ι siRNA effects on phosphorylation status of Bad and Bad/Bcl-xL heterodimerization  
 PKC-ι is overexpressed in non-small cell lung cancer cells (NSCLC) and it has been 
reported to phosphorylate Bad at multiple sites for cell survival [10].  To test whether PKC-ι can 
directly phosphorylate endogenous Bad, Bad protein (200 μg) was immunoprecipitated from 
control siRNA and PKC-ι siRNA treated (incubation time 24 h) RWPE-1 and DU-145 cells.  
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Normal rabbit IgG agarose conjugate (5 μg) was used as a negative control.  Results 
demonstrated no detectable association between PKC-ι and BAD.  We also increased the protein 
level and performed reverse immunoprecipitation with PKC-ι antibody, but no association of Bad 
with PKC-ι was observed.  Whereas immunoblot with phospho specific Bad (ser-112, ser-155, 
ser-136) showed no significant changes in phospho Bad ser-112, phosphorylation of Bad ser-155 
and ser-136 decreased in RWPE-1 cells (Figigure 6.8A; second column).    
 A similar experiment was performed with DU-145 (Figure 6.8A, third column).  First, we 
investigated if PKC-ι associates with Bad.  Our result showed no association of PKC-ι and Bad 
(data not shown).  However, we observed an increase in phosphorylation of Bad ser-112, no 
significant changes in p-Bad (ser-136) and p-Bad (ser-155). 
Our results also showed the disruption of Bad/Bcl-xL heterodimerization in PKC-ι siRNA 
treated cells compared to control siRNA but the anti-apoptotic protein level of Bcl-xL remained the 
same.  The disruption of Bad/Bcl-xL heterodimerization may play a critical role in mitochondria 
dysfunction and apoptosis in PKC-ι siRNA treated cells.  We also found that there were different 
levels of phosphorylation of Bad RWPE-1 and DU145 cells (Figure 6.8A).  All three phospho 
serine sites (112, 155,136) on Bad protein are expressed endogenously in RWPE-1 cells while 
DU-145 cells have only two p-Bad (ser-112 and ser-136) (Figure 6.8B).   Collectively, these 
results suggest that in DU-145 cells, phosphorylation of Bad (deactivation/survival) was not able 
to rescue the cells from PKC-ι siRNA induced apoptosis.
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Figure 6.4 RWPE-1 cells, LNCaP cells and DU-145 undergo apoptosis after treatment with PKC-
ι siRNA. The images of cells treated with control siRNA (RWPE-1: 50 nM; LNCaP:100 nM and 
DU-145:150 nM, respectively) compared to and PKC-ι siRNA treated (the same concentration as 
control) were captured using a digital camera interfaced with an inverted microscope (20x) and 
analyzed using the Scion image program (Scion Corp).  The pictures were taken after 24 h 
incubating with siRNAs complex.  The PKC-ι siRNA treated cells showed cell blebbing, rounding 
and rupturing of cells, which indicates the apoptosis process.
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Figure 6.5 PKC-i siRNA induces apoptosis.  (A) Whole cell extracts of RWPE-1 treated with of 
control siRNA and PKC-ι siRNA treated cells were prepared as described in “Materials and 
Methods” and immunoblot of PARP and cleaved PARP (Asp214), indicate cells undergoing 
apoptosis via activation of caspase-7.  Immunoblot for survivin and cytochrome c further 
demonstrate apoptosis in PKC-ι siRNA treated cells.  Western blot analysis of β-actin shows that 
equal amounts of protein were loaded in each lane.  (B) Similar immunoblots were performed for 
DU-145 cells.  Activation of PARP and caspase-7, combined with an increase in cytochrome c 
and a decrease in survivin indicated apoptosis in DU-145 cells.
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Figure 6.6 Effects of PKC-ι siRNA on LNCaP cells.  Whole cell extracts of LNCaP cells treated 
with control siRNA or PKC-ι siRNA were prepared as described in “Materials and Methods” and 
immunoblot analysis of PARP and cleaved PARP, and survivin demonstrate apoptosis in PKC-ι 
siRNA treated cells.  Western blot analysis of β-actin showed that an equal amount of protein is 
loaded in each lane.
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Figure 6.7 Effects of PKC-ι on cdk7 and cdk2 activity.  A separate experiment was repeated for 
RWPE-1 with control siRNA and PKC-ι siRNA and whole cells extracts (150 μg) were analyzed 
for Cdk7, p-Cdk7 (T170), cdk2, p-cdk2 (T160), and β-actin verified equal loading of protein.
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Figure 6.8 Effects of PKC-ι siRNA on Bad phosphorylation and Bad/Bcl-xL heterodimerization.  
(A)  Both RWPE-1 cells and DU-145 cells were treated with PKC-ι siRNA for 24 h and cell lysates 
(300 μg) were immunoprecipitated with Bad mouse monoclonal agarose-conjugate (5 μg). The 
resulting supernatant and immuocomplex beads were subjected to SDS-PAGE.  The first column 
is the negative control containing normal mouse IgG agarose conjugate with cell lysate.    
Phosphorylation of Bad was analyzed using phospho specific antibodies: Bad ser-112 (S112), 
ser-155 (S155) and ser-136(S136).  Bound Bcl-xL with Bad and unbound Bcl-xL was also 
analyzed. (B) Cell lysates of endogenous protein (1 mg) was immunoprecipitated with Bad and 
different levels of phosphorylation status of Bad between normal RWPE-1 cells, and DU145 cells 
was also examined.
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6.6 Discussion 
 In the previous chapter, we demonstrated that suppressing PKC-ι with PKC-ι siRNA 
decreased cell proliferation and disrupted the cell cycle.  In this chapter, we further demonstrated 
that PKC-ι siRNA leads to cell apoptosis.  Cell death is characterized by morphological changes 
such as cell shrinkage, chromatin condensation and DNA fragmentation [6-7]. 
Transfecting PKC-ι siRNA to all three cells lines produced cells undergoing stress signals 
such as membrane blebbing, rounding of cells, and lifting of cells from cultured flasks.  This 
indicates apoptosis, which consists of intrinsic and extrinsic pathways [50, 51].  The intrinsic 
pathway depends on depolarization of the mitochondria and the extrinsic pathway involves 
activation of death receptors.  Release of cytochorme c, activation of caspase-3, -6, -7 and 
cleaved PARP are relevant biomarkers in apoptosis induction for the intrinsic pathway [52-53].  
All this occurred when PKC-ι was suppressed with PKC-ι siRNA in RWPE-1 cells and DU-145 
cells.  Survivin protein, which regulates cell division and apoptosis, is also linked with “intrinsic” 
apoptosis [53-57] and we showed that survivin is significantly suppressed in PKC-ι siRNA treated 
cells compared to control siRNA in RWPE-1 cells and DU145 cells.  Collectively, the data shows 
that PKC-ι is an antiapoptotic protein and is required for cell survival in both healthy and 
cancerous prostate cells. 
However, PKC-ι siRNA has no signifant decrease in LNCaP cell viability shown 
previously in chapter 5.  Although there was some activation of PARP observed in early 
transfection time, specific cleaved PARP (Asp214) was not observed (data not shown).  In 
addition, there was no activation of caspase-7 and no changes in cytochrome c.  However, 
survivn levels were lower in PKC-ι siRNA treated cells indicating there were some cell death but 
insufficient to induce apoptosis in LNCaP cells.  One possible reason for insufficient effects of 
PKC-ι siRNA is that, there could be rapid syntheis of PKC-ι in LNCaP cells that compete with 
suppression of PKC-ι siRNA.  Secondly, there could be a truncated PKC-ι or mutation point on 
PKC-ι, which failed to recognize by wild type PKC-ι siRNA.  However, this theory is yet to be 
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proven.  There are also other mechanisims such as MAP kinase is involved in LNCaP cells 
survival [58].  Therefore, survival of LNCaP cells involves PKC-ι as an antiapoptotic protein as 
well as other molecular mechanisms. 
Other studies showed that PKC-ι colocalized with CAK/Cdk7 in human glioma cells and 
phosphorylated CAK/Cdk7 during cell cycle progression [59-60).  Similarly, in RWPE-1 cells, we 
found that PKC-ι is transiently associated with Cdk7 which phosphorylates cdk2 and drives cell 
cycle progression (chapter 4).  PKC-ι may be required for cell proliferation of RWPE-1 cells, 
because suppressing PKC-ι siRNA caused cell cycle arrest at G2/M, a decrease in 
phosphorylation of Cdk7 and cdk2 as well as apoptosis. 
There are a number of substrates for PKCs [61-62].  In particular, PKC-ι has been shown 
to phosphorylate Bad at three different serine sites; ser-112, ser-155, and ser-136 for survival in 
non-small-cell lung cancer (NSCLC) [61].  Bad is a proapototic protein that can translocate from 
cytosol to nucleus and disrupt Bad/Bcl-2/Bcl-xL heterodimerization, leading to apoptosis.  
Phosphorylated Bad (inactivated Bad) is then sequestered by 14-3-3 proteins for cell survival [63, 
64].  We also found that immunoprecipitation with either Bad antibody or PKC-ι antibody showed 
no association of Bad and PKC-ι in both normal prostate and carcinoma prostate cell lines (data 
not shown).  Transient suppression of PKC-ι also induced no significant changes in phospho Bad 
ser-112, but there was a decrease in phospho Bad ser-155 and ser-136 in RWPE-1 cells.  A 
slight increase in association of Bad/Bcl-xL was also observed in PKC-ι siRNA treated cells, 
meaning proapototic Bad quenched the antiapoptotic protein, Bcl-xL, leading to cell death of 
RWPE-1 prostate cells.  However, in DU-145, phosphorylation of Bad increased at ser-112, while 
ser-136 showed no significant change in phosphorylation. 
Phosphorylation of Bad at serine-155 was not observed in endogenous protein levels.  
An increase in phosphorylation of Bad could be due to Akt/PKB which mediates phosphorylation 
of Bad at serine 136; while RSK2/PKA/PAK is involved with phosphorylation of Bad at serine 112 
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and 155 [65].  We also observed reduced disassociation of Bad/Bcl-xL. Taken together, PKC-ι 
may not directly involved in phosphorylation of Bad in prostate cells. 
However, transient suppression of PKC-ι may indirectly influence mitochondrial 
dysfunction, independent of phosphorylation of Bad, and lead to apoptosis in both RWPE-1 cells 
and DU145 cells.  Our results indicate that RWPE-1 and DU145 cells have a different Bad 
phosphorylation pattern.  In RWPE-1 prostate cells, there is an endogenous level of phospho Bad 
at ser-112, ser-136 and ser-155.  In DU145 cells, p-Bad ser-112 and p-Bad ser-136 were present.  
It is reasonable to assume that there could be kinetic effects between phosphorylation of Bad and 
PKC-ι (an anti-apoptotic protein).  An increase in phosphorylated proapototic Bad did not 
overcome the suppression of anti-apoptotic PKC-ι in prostate cancer cells. 
It has been hypothesized that a balance between prosurvial and prodeath Bcl-2 family 
members determines whether a cell lives or dies [66], but the precise molecular mechanisms of 
how membrane-bound Bcl-2 proteins exert their control over caspase activation and apoptosis is 
still unclear. Antiapoptotic Bcl-xL protein is overexpressed in prostate cancer cells and 
downregulation of Bcl-xL leads to TGF-βΙ induced apoptosis [67-68].  Bcl-xL also participates with 
Bcr-Abl, a protein responsible for chemotherapeutic resistance and mediates apoptosis in 
transformed pro-myelocytic HL-60 cells [69].  Taxol and 2-methoxyestradiol (2-ME) induced 
phosphorylation of Bcl-xL at serine 62 results in apoptosis of prostate cancer cells [70].  In 
addition, Bcl-xL has been shown to be overexpressed in many tumor cells leading to cell survival 
[71].   Our study found no decrease in Bcl-xL protein level or changes in phosphorylation status of 
Bcl-xL.  PKC-ι siRNA increased the association of Bad/Bcl-xL in RWPE-1 cells, but disassociated 
Bad and Bcl-xL in DU145 cells, leading to mitochondrial dysfunction and apoptosis. 
In summary, suppression of PKC-ι leads to cell cycle arrest and apoptosis in both 
RWPE-1 and DU-145 cells, independent of Bad phosphorylation.  However, we suggest that anit-
PKCι chemotherapy may be a viable option for the treatment of prostate cancer since normal 
untransformed prostate cells do not divide at the same rate as prostate carcinoma cells.  
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Therefore, suppression of PKC-ι in prostate carcinoma may inhibit cancer cell proliferation with 
little effect on normal prostate cells. 
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Chapter 7 
Atypical PKCs activates NF-kappa B pathway in prostate cells 
 
7.0  Introduction 
Atypical PKCs have been shown to control nuclear factor kappaB (NF-κB) and it plays a 
critical role in the development of human diseases such as cancer and inflammation [1-4].  There 
are five members of the mammalian NF-κB family, p65 (RelA), Rel-B, c-Rel, p50/p105 (NF-κB1), 
and p52/p100 (NF-κB2).  They exist in unstimulated cells as homo- or heterodimers bound IκB 
family proteins for example, IκBα, IκBβ, IκBε and IκBγ (Figure 7.1) [5].  NF-κB can be stimulated 
by inflammatory cytokines such as Tumor Necrosis Factor (TNF)-α and Interleukin (IL)-1 [6].  
Upon stimulation, IκB kinase (IKK) is phosphorylated (activated) which triggers NF-κB 
downstream effectors.  IKK complex consists of two catalytic subunits (IKKα and IKKβ) and an 
adapter protein IKKγ or Nemo [6].  
 
7.1 NF-κB signal transduction cascade   
  NF-κB proteins have a conserved 300 amino acid Rel homology domain (RHD) that is 
located toward the N-terminus of the protein and is responsible for dimerization, interaction with 
IκBs, and binding to DNA [7-8].  The most classical (canonical) form of NF-κB is the heterodimer 
of p50 and p65 (Rel A), which is kept in the cytosol by an inhibitor protein, IκBα, preventing 
nuclear translocation and activity (Figure 7.2).  Upon stimulation by cell inflammatory cytokines 
such as TNFα, IκBα is phosphorylated on serine residues 32 and 36 by IκB kinase (IKK) 
complex.  This leads to ubiquitination and subsequent degradation of IκBα through the 26S 
proteosome pathway [3-4].  The liberated NF-κB/p65 is translocated to the nucleus where they 
bind to the promoter regions of κb sites with the consensus sequence GGGRNNYYCC (N = any 
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base, R = pruine, and Y – pyrimidine).  This results in an activation of NF-κB-responsive genes 
and in increased gene expression [8-10]. 
In the alternative (non-canonical) pathway, NF-κB is induced in response to stimuli such 
as B cell-activating factor (BAFF), CD40 ligand and LTβR.  It has slower activation kinetics than 
the canonical pathway.  IKKα is required for NF-κB-inducing kinase (NIK), which activates RelB-
p100 and is processed to RelB-p52, which leads to nuclear accumulation of RelB-p52 dimers.  
The dimer binds to the promoter regions of NF-κB-responsive genes and activates gene 
expression [11-15]. 
 
7.2  IKK activation 
 For upstream IKK activation, protein-protein interactions are critical events in the 
signaling cascades activated by TNFα.  The main inducer of TNFα is the TNF Receptor-1 (TNFR-
1), a 55 kDa protein with the death domain (DD) in its intracellular region (Figure 7.3A) [16].  
Upon cell stimulation, the TNFR-1-associating-death-domain (TRADD) strongly interacts with 
TNFR-associated-factor-2 (TRAF2) and Receptor Interacting Protein (RIP).  The recruitment of 
adapter proteins allows interaction with another adaptor protein p62, which links atypical PKCs to 
the activation of NF-κB by the TNFα signaling pathway [1, 17].    Similiarly, IL-1 can activate 
aPKCs via MyD88, a functional analogue of TRADD (Figure 7.3B).  The enzymatic interaction 
between DD and MyD88 is required for NF-κB activation [1].  Activation of IKK complex by TNFα 
and Il-1, results in phosphorylation of specific serine residues within the activation loop of IKKα 
and IKKβ.  For example, IKKα is phosphorylated on two sites within activation loop of the kinase 
domain: serine 176 and serine 180 while IKKβ is phosphorylated on serine 177 and serine 181 [6, 
18].  MAP kinase and aPKCs have been shown to phosphorylate IKKα/β [19-20]. 
 In this experiment, we further demonstrate that atypical PKCs are required for prostate 
cell survival.  Particularly PKC-ι activates IKK kinases and triggers NF-κB survival cascades in 
prostate cells.
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Figure 7.1 Schematic representation of NF-κB, IκB and IKK proteins family [37].
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         Classical NF-κB Pathway                      Alternative NF-κB Pathway
 
 
 
Figure 7.2 Classical and alternative pathways of NF-κB activation [37]. 
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Figure 7.3 Activation of aPKCs by cytokines.  Signaling cascade activated by cytokines such as 
TNFα (A) and IL-1 (B).   TNFα and IL-1 induces TNF Receptor-1 (TNFR-1) or MYD88 a functional 
analog of TRADD with a death domain (DD) in its intracellular region.  Upon stimulation, a 
receptor interacting protein (RIP) and an adptor protein (p62) serves to locate aPKC in the NF-κB 
signaling cascades [1].
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7.3  Materials and Methods 
7.3.1 Reagents and Antibodies. 
 Polyclonal primary antibodies were purchased from the following companies: IKK-α/β (sc-
7607), IκBα(sc-371), β-actin (sc-1616), NF-κB p65 (sc-375), p-IκBα (sc-21689-R), IKKα(sc-
7218), PARP (sc-7150), caspase-7 (sc-13560), and mouse monoclonal surviving (sc-17779)  
(Santa Cruz Biotechnology, CA); Anti-PKC-ι mouse monoclonal catalog number 610176 
(Transduction Laboratory, Lexington, KY); rabbit polyclonal cleaved PARP (Asp 214) (catalog 
number 9541), p-IKKα/β catalog number 26875 (Cell Signaling Technology, Danvers, MA); 
Secondary antibodies were purchased from the following companies: HRP Goat x Mouse IgG 
catalog number JGM035146, HRP Goat x Rabbit IgG (catalog number JGZ035144) (Accurate, 
Westbury, NY);  HRP Bovine anti-goat IgG (sc-2350) (Santa Cruz Biotechnology, CA); Anti-rabbit 
IgG HRP-linked antibody (catalog number 7074) (Cell Signaling Danver, MA).  Normal rabbit IgG 
(catalog number 12-370) (Upstate).  For immunoprecipitation anti-rabbit IgG (whole molecule)-
agarose beads (1:1 v/v) (catalog number A8914) (Sigma, St. Louis, MO); TNF-α was purchased 
from Calbiochem (catalog number 654205).  All other chemicals and reagents were commercially 
obtained from Sigma Aldrich, St. Louis, MO; Fisher Scientific, Norcross, GA; Pierce, Rockford, IL; 
and Bio-Rad Richmand, CA; unless otherwise stated. 
7.3.2 Cell Culture. 
 RWPE-1, LNCaP and DU-145 cell lines were obtained from American Type Tissue 
Culture Collection (ATCC) (Rockville, MD). LNCaP cells were grown in RPMI1640. DU-145 cells 
were grown in  Minimum Essential Medium Eagle (MEME) earle’s balanced salt solution.  Both 
RPMI1640 and MEME media were supplemented with 10% fetal bovine serum (FBS), and 
antibiotics 5ml (penicillin 10 U/ml and streptomycin 10 μg/ml). For RWPE-1, cells were grown in 
Keratinocyte Serum Free Media, containing Epidermal Growth Factor (2.5μg) and Bovine 
Pituitrary Extract (25 mg) (GIBCO) and antibiotics 5ml (penicillin 10 U/ml and streptomycin 10 
μg/ml).  All cell lines were grown in a 5% CO2 incubator at 37 oC. 
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7.3.3 TNF-α Treatment 
 Cells (3.75 x 105) were grown as monoloayer in T75 flasks.  After incubation for 24 h, the 
cells were treated with TNF-α (20 ng/ml).  At indicated times, cells were trypsinized, pelleted, 
washed with 1ml of PBS, resuspended in 0.4% Trypan Blue Solution (Sigma), and counted using 
a hemacyometer. Live (dye excluded) cells were counted.  The results from three seperate 
independent experiments were used to determine the mean viability and standard deviation for 
each time point.  
7.3.4 Immunoprecipitation and Western Blot analysis 
 After treatment with TNFα (20 ng/ml), cells were placed on ice to terminate the 
incubation. Whole cell lysates of 100 μg were immunoprecipitated as described in Chapter 4, 
section 4.3.1 with 5 μg of PKC-ι rabbit polyclonal antibody (5 μg) and PKC-ζ rabbit polyclonal 
antibody (5 μg), respectively.   Western blots were performed using their repective primary 
antibody according to “Material and Methods” described in Chapter 3, section 3.1.5). 
7.3.5 Preparation of cytosol and nuclear extracts.  
Cells were washed twice with cold PBS and resuspended in hypotonic Buffer A [50 mM 
HEPES, pH 7.4), 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM PMSF, 2.5 
μg/m leupeptin, 0.15 U/ml aprotinin. The lysates were centrifuged at 4, 000 g for 30 min at 4 oC 
and the supernatants (cytoplasmic proteins) were collected.  The pelleted nuclei were extracted 
with Buffer A containing 400 mM KCl and 0.5% Triton X100.  After centrifugation at 14 000 g for 
30 min at 4 oC, the supernatant containing nuclear extracts was collected. 
7.3.6 Kinase assay 
DU-145 cells (3.75 x 105) were grown as a monolayer in T75 flasks overnight.  The 
following day, the cells were placed on ice and cell lysates were prepared according to methods 
described in Chapter 4, section 4.3.1.  Whole cell lysates of (100 μg) were immunoprecipitated as 
follows:  cell lystaes (50 μg) were pre-cleared for 30 min at 4 oC with anti-rabbit IgG-agarose 
beads (1:1 v/v, 10 μl) (catalog number A8914; Sigma Aldrich) and incubated with 5 μg of PKC-ι 
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rabbit polyclonal antibody and/or IKKα/β rabbit polyclonal antibody (5 μg) overnight at 4oC and 
then a further 1 h with anti-rabbit IgG-agarose beads (1:1 v/v, 50 μl).  The immunoprecipitated 
samples were incubated with kinase buffer (50 μl of 3.03 mg/10 ml ATP, 30 mM of Tris p.H 7.4, 
50 μl of 5 μg phosphotidylserine) at 30 oC in a water bath for 5 minutes.  The reaction was 
terminated by placing the samples in ice.  The PKC-ι inhibitor 1H-imidazole-4-carboxamide, 5-
amino-1-[2,3-dihydroxy-4-[(phosphonooxy) methyl]cyclopentyl]-,[1R-(1a, 2b, 3b, 4a)]  (ICA-1; 100 
nM) was synthesized by Southern Research Institute (Birmingham, AL). 
The first negative control was immunoprecipitated with normal rabbit IgG beads with cell 
lysates (50 μg); the second negative control included cell lysate (50 μg) plus normal rabbit IgG (5 
μg).  The kinase reaction was performed as described above.   Protein samples were separated 
by 10% SDS-PAGE and electroblotted onto supported nitrocellulose paper.  Each blot was 
blocked for 1 h with 5% fat-free milk TTBS solutions at room temperature. 
Protein bands were probed with their repective primary antibody p-IKKα/β rabbit 
polyclonal antibody (5 μg, 1:1000 dilution).  Mouse monoclonal PKC-ι ( 5 μg, 1:1000 dilution).   All 
the Immuoreactive bands were visualized with chemiluminescence according to the 
manufacturers’ instructions (SuperSignal West Pico Chemiluminescent Substrate; PIERCE, 
Rockford, IL). 
7.3.7 Prostate tissue analysis 
  Normal prostate tissues (9 specimens) were purchased from Tissue Network.  The 
cancer prostate tissues were obtained from prostectomy from patients from May - August 2007.  
The specimens were placed on ice immediately after prostactomy, frozen in liquid nitrogen within 
30 minutes to 1 hour after prostectomy.  Prostate tissues (0.5-1g) were homogenized with 2 ml of 
complete lysis buffer and centrifuge at 40 000 g.  The tissue lysates (100 μg) were Western 
blotted for PKC-ι using PKC-ι mouse monoclonal antibody (5 μg, 1:4000 dilution).
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7.4 Results 
7.4.1 Susceptibility of RWPE-1, LNCaP and DU-145 cells to TNF-α treatment. 
 There is accumulating evidence that an activated NF-κB pathway leads to prostate 
cancer cell survival [21-23].  Three prostate cell lines RWPE-1, LNCaP and DU-145 were treated 
with TNFα (20 ng/ml) for 24, 48, and 72 hours.  Viable cells were counted at indicated times using 
trypan blue exclusion assay.  Results demonstrated that LNCaP cells were sensitive to TNFα and 
inhibited their growth rate (Figure 7.4B).  RWPE-1 cells were slightly sensitive to TNFα while DU-
145 were insensitive to TNFα (Figure 7.4A, C).  To investigate if TNFα is signaling through NF-
κB, Western blots were performed for the presence of IκBα in these cells.  Results show that 
IκBα was degraded in RWPE-1 cells and LNCaP cells. 
However, there was no significant degradation of IκBα in DU-145 cells (Figure 7.5A).  
The insignificant degradation of IκBα in DU-145 cells could be due to the rapid turnover; i.e. rapid 
phosphorylation and degradation of IκBα in DU-145 cells [23-24]. 
Therefore, we changed the incubation time to a shorter period from 10-30 minutes.  
Results demonstrated IkBα degradation in all three cell lines (Figure 7.5B).  Western blot for β-
actin in these samples showed equal loading of proteins.  These results suggest that TNFα 
induces NF-κB activation. 
7.4.2 Involvement of aPKCs in activation of IKKα/β. 
 Previous studies have demonstrated that atypical PKCs are involved in TNFα activation 
of the NF-κB pathway [17].  We therefore determined if endogenous PKC-ι is involved in TNFα 
induced IKKα/β activation in prostate cell lines.  Since, DU-145 displayed faster turnover of IκBα, 
the activation of IKKα/β is likely to be constitutive and rapid as well.  Therefore, we treated TNFα-
resistant cell lines RWPE-1 with TNFα for a short incubation time (T = 10, 20, 30 min). We found 
no association of PKC-ι with IKKα/β in RWPE-1 cells (Figure 7.6A).  We also tested longer 
incubation times (T = 24, 48, 72 h) with TNFα to determine the association of PKC-ι and IKKα/β, 
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but there were none in RWPE-1 cells (data not shown).  However, immunoprecipitation with PKC-
ζ rabbit polyclonal demonstrated PKC-ζ and IKKα/β association at 10 min post TNFα treatment.  
Downregulation of IκBα was also observed (Figure 7.6B).  Phosphorylation of IKKα/β 
(Ser176/180) was observed at 30 min, while rapid association and dissociation of IκBα was 
observed at 10-30 min (Figure 7.6C).  Taken together, TNFα induce PKC-ζ leads to activation of 
IKKα/β  and NF-κB transactivation in RWPE-1 cells. 
 Contrary to RWPE-1 cells, DU-145 cells showed an association of PKC-ι and IKKα/β at 
10 min post TNFα treatment in DU-145 cells (Figure 7.7A).  Additionally, IκBα protein co-
immunoprecipitated with the PKC-ι/IKKα/β complex (Figure 7.7A).  For specificity, we showed 
that both IKKα and IKKβ associated with PKC-ι in TNFα treated cells at 20 and 30 minutes 
respectively (Figure 7.7B).   We also observed phosphorylation of IKKα/β (ser176/180) at 30 
minutes post TNFα treatment, and phosphorylation of IκBα (Ser32) co-immunoprecipitated with 
the PKC-ι/IKKα/β complex (Figure 7.7C).  Besides PKC-ι, PKC-ζ has been shown to be involved 
with IKK activation [29].  Therefore, we immunoprecipitated PKC-ζ and found that both 
IKKα/β and IκBα associated with PKC-ζ (Figure 7.7D).  However, phosphorylation of IKKα/β was 
not observed (data not shown).  This finding suggests that in DU-145 cells, TNFα induces PKC-ι 
activation of IKKα/β and subsequent phosphorylation of IκBα (Ser32) leads to NF-κB activation.  
It is possible that there is a shift from PKC-ζ in transformed nontumorigenic RWPE-1 to PKC-ι in 
DU-145 carcinoma cells in the IKK activation pathway. 
 Although, LNCaP cells are sensitive to TNFα treatment, there have been reports that 
IKKα is weakly activated in LNCaP cells [24, 25].  In our experiment, LNCaP cells treated with 
TNFα did not induce PKC-ι or PKC-ζ in activation of IKKα/β (data not shown).  Therefore, our 
results demonstrated that constitutive activation of NF-κB in hormone-insensitive prostate DU-
145 carcinoma is a consequence of IKKα/β activation but not in the hormone responsive LNCaP 
cell line [25]. 
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7.4.3 Translocation of p65 from cytosol to nucleus in DU-145 cells. 
 Many studies have shown that upon stimulation of cells with cytokines such as TNFα, 
IKKs phosphorylate IκBα at serine residues 32 and 36 [26-28].  After phosphorylation, IκBα is 
ubiquitinated and subsequently degraded by 26S proteasome.  This allows translocation of NF-
κB/p65 from cytosol to the nucleus where it binds to targeted sites in DNA for transcription [29].  
To test this process, DU-145 cells were treated with TNFα and cytosol and nuclei fractions were 
separated.  Western blot analysis shows translocation of p65 from cytosol to nucleus (Figure 7.8).  
This corresponds to other studies of NF-κB/p65 translocation to nucleus to function in 
transcription [25, 30].  These findings support a novel link between PKC-ι and the NF-κB pathway 
in prostate cancer cell survival. 
7.4.4 TNFα induces apoptosis in LNCaP cells. 
 It has been demonstrated that TNFα induces apoptosis in androgen receptor positive 
LNCaP cells [34].  Our data also demonstrated that LNCaP cells undergo apoptosis after long 
incubation with TNFα (Figure 7.9). Western blot of cleaved PARP (Asp214), activation of 
caspase-7 (20 kDa) and a decrease in survivin indicated cells undergoing apoptosis.  However, 
RWPE-1 and DU-145 cells are resistant to apoptosis.  There was no cleaved PARP, no activation 
of caspase-7, and presence of survivin. 
Hence, our data is in accordance with other reports that LNCap cells are sensitive to 
TNFα while RWPE-1 and DU-145 are resistant to TNFα treatment. 
7.4.5 In vivo kinase assay and ICA-1 effects on prostate cells. 
 It has been demonstrated that PKC-ι/ζ phosphorylates IKKα/β [36, 42].  To further 
demonstrate that IKKα/β is a true substrate of PKC-ι, IKKα/β and PKC-ι were co-
immunoprecitpitated and Western blots of p-IKKα/β (Ser176/180) demonstrated that PKC-ι 
phosphorylates IKKα/β (Figure 7.10A).  Little or no activation of IKKα/β was observed in control 
immunoprecipitated PKC-ι or IKKα/β samples.  Additionally, activation of IKKα/β was inhibited 
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when the putative PKC-ι inhibtor ICA-1 (100 nM) was incubated in co-immunoprecipitated PKC-ι 
and IKKα/β.  The inhibitor binds to the kinase domain amino acid sequence 469-475. 
However, ICA-1 does not significantly ( p > 0.05 for both cell lines) inhibit the cell 
proliferation of LNCaP or DU-145 cells (Figure 7.10B, C).  Interestingly, low concentration of ICA-
1 (0.1- 0.5 μM) resulted in an increase in cell numbers while high concentration of ICA-1 (10-60 
μM) resulted in a inhibition of cell growth.  It is possible that ICA-1 could be an activator at low 
concentration and an inhibitor at high concentration.  However, this theory is yet to be proven.  
Whether ICA-1 specifically inhibits PKC-ι and not other PKC isoforms remains unknown. 
7.4.6 PKC-ι is overexpressed in PIN and tumor tissues. 
 We have demonstrated that PKC-ι is antiapoptotic and is involved in prostate cell 
proliferation in tissue culture.  We further analysed some prostate tissues obtained form tissue 
network and from patient samples.  Benign prostatic hyperplasia (normal), prostate intraepithelial 
neoplasia (PIN), and tumor samples were homogenized and tissue lysates (100 μg) were Westrn 
blotted for PKC-ι (Figure 7.11A, B).  Our data demonstrated that PKC-ι is overexpressed in PIN 
and tumor tissues compared to normal prostate tissues.  PKC-ι absorbance densitometry 
demonstrates that there was an 8-fold increase in PIN tissues and 100 fold increase in tumor 
tissues compared to normal prostate tissues (Figure 11C). 
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Figure 7.4 Effects of TNFα treatment on prostate cells. Normal RWPE-1 prostate cells (A), LNCaP prostate cells (B) and DU-145 prostate 
cells (C) were used.  Forty to fifty percent confluent cells (3.75 x104) were seeded in a T75 flask.  After incubation for 24 hours, the cells 
were treated with 20 ng/ml of TNFα for 24-72 hours.  At the indicated time, both the control cells and TNFα treated cells were trypsinized 
and viable cells were counted using trypan blue exclusion assay and a hematocytometry.  Triplicate experiments were performed for each 
cell line.  The mean values of viable cells with SD were plotted. 
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Figure 7.5 TNFα treatment induces IκBα degradation. (A) After determining the cell viability (Fig. 1), the left over cells population were 
immunoblotted for IκBα.  RWPE-1 and LNCaP cells show a significant degradation of IκBα while DU-145 cells showed no changes in 
IκBα.  The membrane was reprobed for β-actin indicated that equal amounts of protein (50 μg) were loaded in each lane.  (B)  In another 
independent experiment, cells were treated with TNFα (20 ng/ml) for a short incubation time (T=10, 20, 30 min).  Whole cell lysates (50 
μg) showed a time dependent IκBα degradation in all three cell lines. The membranes were reprobed for β-actin and depicted an equal 
amount of protein loaded in each lane.
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Figure 7.6 Role of PKC-ι in activation of IKKα/β.  Forty to fifty percent confluent RWPE-1 cells 
(3.75 x104 cells/flask) were seeded in a T75 flask.  After incubation for 24 hours, the cells were 
treated with 20 ng/ml of TNFα for a short incubation time (T=20, 20, 30 min).  At indicated time, 
the flasks were placed on ice and cells were washed cold with DPBS to terminate TNFα 
incubation. (A) RWPE-1 whole cells extracts (100 μg) from each time point were 
immunoprecipitated with rabbit polyclonal PKC-ι antibody.  Column 1 is the positive (+) control 
(50 μg of whole cell extracts).  Column 2 is the two negative controls: first is the sepharose beads 
(50 μl of 1:1 v/v), the second negative control contains sepharose beads and rabbit IgG.  Western 
blot analysis of IKKα/β shows no association of PKC-ι and IKKα/β in RWPE-1 cells treated with 
TNFα. The membrane was reprobed for PKC-ι.  (B)  In another independent experiment, both 
control and TNFα treated cells were immunoprecipitated with rabbit polyclonal PKC-ζ antibody.   
The physical association of PKC-ζ and IKKα/β was observed at 10 min post-TNFα treatment.   
IκBα was also co-immunoprecipitated.  (C) In a similar experiment, there is phosphorylation of 
IKKα/β (Ser 176/180) at 30 min and phospho-IκBα (Ser32) at 10 and 30 min post-TNFα 
treatment.
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Figure 7.7 PKC-ι activates IKKα/β in DU-145 cells.  Similar experiments were performed as 
described in Figure 3 and in “Materials and Methods”.  (A) DU-145 whole cells extracts (100 μg) 
from each time point were immunoprecipitated with rabbit polyclonal PKC-ι antibody.  Column 1 
is the positive (+) control (50 μg of whole cell extracts).  Colum 2 depicts the two negative 
controls: first is the sepharose beads (50 μl of 1:1 v/v), the second negative control contains 
sepharose beads (50 μl) and normal rabbit IgG.  Western blot analysis of IKKα/β shows an 
association of PKC-ι and IKKα/β in cells treated with TNFα.  The membrane was reprobed for 
PKC-ι.  (B)  Using specific antibodies such as anti-IKKα and anti-IKKβ demonstrated that PKC-ι 
is associated with both IKKα and IKKβ.  (C)  Western blots of p-IKKα/β (Ser 176/180) at 30 min 
post-TNFα treatment and p-IκBα (Ser32) at 20 and 30 min post-TNFα was also co-
immunoprecipitated with PKC-ι.  (D)  In another independent experiment, both control and TNFα 
treated cells were immunoprecipitated with rabbit polyclonal PKC-ζ antibody.   The physical 
association of PKC-ζ and IKKα/β was observed at 30 min post-TNFα treatment and IκBα was 
also co-immunoprecipitated.   
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Figure 7.8 Translocation of IκBα from cytosol to the nucleus.   Similar density (3.75 x 104 cells/flask) of RWPE-1, LNCaP and DU-145 
cells were treated with TNFα (20 ng/ml).  The cytosol and nucleus were separated as described in “Materials and Methods”.   Cytosol 
extracts (10 μg) of RWPE-1 cells demonstrated a decrease in IκBα at 10 and 20 min while an increase in IκBα in the nucleus at 20 min 
post-TNFα treatment.  Similar pattern was observed with both LNCaP and DU-145 cells treated with TNFα demonstrating translocation of 
NF-κB/p65 to the nucleus. 
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Figure 7.9 Treatment of TNFα induces apoptosis in LNCaP cells.  A cell density of 3.75 x 104 
cells were seeded and cultured for 24 hour.  The following day the cells were incubated with 
TNFα for 72 hours.  Whole cell lysates of 100 μg were separated on 12% SDS-PAGE.  RWPE-1 
and DU-145 cells demonstrated the presence of full PARP, pro caspase-7 and survivn in both 
control and TNFα treated cells.   Western blot of cleaved PARP (Asp214), activation of caspase-7 
(20 kDa) and a decreased in survivn demonstrated that TNFα induced apoptosis in LNCaP cells. 
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Figure 7.10 In vivo kinase assay and the effects of ICA-1 treatment on RWPE-1 and DU-145 
cells.  (A) Cell lysates (50 μg) of an exponentially growing DU-145 cells were immunoprecipitated 
with either rabbit polyclonal PKC-ι antibody and/or IKKα/β rabbit polyclonal antibody.   Lane 1 
and 2 are the two negative controls: first is the sepharose beads (50 μl of 1:1 v/v), the second 
negative control contains sepharose beads (50 μl) and normal rabbit IgG.  After 
immunoprecipitation, a kinase reaction was performed according to “Materials and Methods”.  
Western blot analysis showed presence of phospho-IKKα/β (Ser176/180) in lane 3.  Upon 
incubation with PKC-ι inhibitor (ICA-1; 100 nM) phosphorylation of IKKα/β was inhibited.  (B) 
LNCaP and DU-145 cells (C) (50 x104) were seeded in a T25 flask.  After incubation for 24-72 
hours with ICA-1 (0.1 μM-60 μM), both the control cells and ICA-1 treated cells were trypsinized 
and viable cells were counted using trypan blue exclusion assay and a hematocytometry.  
Triplicate experiments were performed for each cell line.  The mean values of viable cells with SD 
were plotted.  P>0.05 demonstrated an insignificant effect of ICA-1 on cell proliferation.
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Figure 7.11 PKC-ι expression in prostate tissues.  (A)  Normal prostate (N) and prostate 
intraepithelial neoplasia (P) were obtained from Tissue Network.  Tissue lysate (100 μg) was 
used for western blot.   Normal prostate tissue has very little or no PKC-ι expression while PIN 
tissues shows overexpression of PKC-ι.  (B) Prostate malignant tissues (M) show overexpression 
of PKC-ι compared to normal prostate tissues.  Western blot for β-actin demonstrates equal 
loading of each sample. (C) PKC-ι absorbance arbitrary value were plotted with p values of P = 
0.00048 (normal vs. malignant), P = 0.0357 (normal vs. PIN), and P = 0.0257 (PIN vs. malignant).
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Table 7:  Summary of NF-κB activation in prostate cells. 
 RWPE-1 LNCaP DU-145 
PKC-ι/IKKα/β - - + 
PKC-ζ/IKKα/β + - + 
IκBα degration + + + 
NF-κB transloation + + + 
Cleaved PARP - + - 
Caspase-7 activation - + - 
Suvivin + - + 
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7.5 Discussion 
 There is growing evidence that NF-κB is implicated in oncogenesis [31, 32].  In addition, 
NF-κB has been shown to prevent cell death in many cancer cells after chemotherapy, 
radiotherapy or TNFα treatment [21-23].  Constitutive activation of NF-κB has been detected in 
androgen-independent prostate cancer xenografts, cell lines and in prostate cancer tissue [33, 
34].  The interaction between the death domain (TRADD, TRAF2, FADD, and RIP) and aPKCs 
have been extensively studied by Moscat et al [17, 35].  In addition aPKC is involved in IKK 
activation and the NF-κB pathway [17, 35-36].  NF-κB transcriptional activity is controlled by an 
antiapoptosis genes such cIAP1, cIAP2, and IEX-1L [37, 38]. 
In prostate cancer, nuclei localization and overexpression of NF-κB has been 
demonstrated in prostate tissue [21, 39].  Although NF-κB pathway has been extensively studied 
in prostate cancer, we further demonstrated that aPKC are specifically activate TNFα-induced 
NF-κB pathway.  In accordance with previous reports, TNFα (20 ng/ml) induces significant cell 
death in LNCaP cells while RWPE-1 cells show a slight sensitivity [34].  However, DU-145 cells 
are insensitive to TNFα (20 ng/ml)  treatment [22].  It has been reported that higher concentration 
of TNFα (100 ng/ml) treatment induces significant growth inhibition in DU-145 and PC-3 cells 
[22].  This discrepancy is due to the differences in TNFα concentration used.  We used a lower 
concentration of TNFα to demonstrate PKC-ι induction in IKK activation.  Upon cell activation by 
TNFα, IκBα is phosphorylated at serine 32 and 36, which triggers the ubiquitination and 
subsequent degradation of IκBα [40, 41].  Our experiments showed degradation of IκBα in 
RWPE-1 cells, LNCaP and cells but there was no significant degradation of IκBα in DU-145 cells.  
One possible reason is that in androgen-independent prostate cancer cells, there is rapid 
phosphorylation and rapid degradation of IκBα (i.e. faster turnover) [23-25].  In addition, the IκBα 
half-life is shorter in DU-145 cells (30 minutes) compared to LNCaP cells (60 minutes) [23]. 
Therefore, a shorter incubation time (10-30 min) was chosen for all three cell lines.  We 
observed a significant degradation of IκBα in all the three cell lines within 10-30 minutes of 
 146
incubation with TNFα (20 ng/ml).  Hence, our data demonstrated the involvement of NF-κB 
activation in TNFα treated cells.  Another key regulator of NF-κB is the activation of upstream 
kinases IKKs [22, 23, 29].   Atypical PKCs have been shown to activate IKKs [17, 42-43].  
Therefore, immunoprecipitation with PKC-ι demonstrated that in DU-145 cells, TNFα induced 
PKC-ι and activation of both IKKα and IKKβ.  IκBα was also coimmunoprecipitated with PKC-
ι/IKKα/β complex.  Phosphorylation of IKKα/β (serine 176/180) and phosphorylation of 
IκBα (serine 32) was also observed in TNFα treated DU-145 cells.  This strongly indicates that 
TNFα induced PKC-ι activation of IKK, and subsequently phosphorlyation of IκBα.  This enables 
NF-κB/p65 to translocate to nucleus for transcription.  Besides PKC-ι, PKC-ζ has been involved 
in activation of IKK [35-36].  Therefore, we immunoprecipitated PKC-ζ from TNFα treated cells.  
Results demonstrated that PKC-ζ is physically associated with IKKα/β at 30 minutes post TNFα 
treatment.  However, phosphorylation IKKα/β was not observed.  It is likely that to a lesser extent, 
PKC-ζ may be involved in TNFα induced IKK activation in DU-145 cells. 
Similar experiments were performed in TNFα resistant RWPE-1 cells.  We found no 
association of PKC-ι and IKKα/β but there was a strong physical association between PKC-ζ and 
IKKα/β in TNFα treated cells.  Moreover, there was an association at 10 minutes post-TNFα 
treatment followed by disassociation of IκBα with the PKC-ι/IKKα/β complex.  Similarly, 
phosphorylation of p-IκBα (serine 32) was observed with PKC-ι/IKKα/β complex.  After 
phorylation, IκBα is degradted by the proteosome [23-24].   Our results strongly suggest that 
TNFα induced PKC-ζ in activation of IKKα/β in RWPE-1 cells. 
However, in LNCaP cells, there was very little or no association between atypical PKC-ι/ζ 
and IKKα/β.   Although TNFα decreased the levels of IκBα expression in LNCaP cells, 
presumably due to increased degradation of IκBα, indicates activation of the NF-κB pathway [25].  
However, NF-κB activation in LNCaP cells is not constitutive compared to androgen-independent 
prostate carcinoma DU-145 and PC-3 cells [23-24].  Moreover, LNCaP cells have low IKKα basal 
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level and minimal IKKα activity [25].  Therefore, it is possible that there is little or no association 
between PKC-ι and IKKα/β in LNCaP cells.  Although the mechanism by which constitutive NF-
κB activation occurs is still unclear, we find that the nature of the alterations in upstream signaling 
pathways that result in constitutive IKK activation in prostate cancer cells may vary.   Moreover, 
members of the MAPK kinases (MAPKKs) have been implicated in IKKα activation [24, 44].  
Studies have further demonstrated that the tumor-suppressor PTEN inhibits NF-κB activation and 
has been implicated in prostate cancer [45].   DU-145 cells are able to secrete large amounts of 
interleukin-6 and other cytokines, whereas LNCaP cells secrete much lower levels.  Chronic 
autocrine stimulation of the NF-κB may therefore account for constitutive NF-κB activation in DU-
145 cells [46-47].  However, whether interleukin-6 (or other factors) secreted by DU-145 cell is 
the consequence of NF-κB activation is not known.  An alternative mechanism for constitutive 
activation of NF-κB in DU-145 is activation of an internal signal transduction pathway.  For 
example, overexpression of the anti-apoptotic protein bcl-2 can activate NF-κB and suppress 
apoptosis [48-49].  Activation of IKKα/β subsequently phosphorylates inhibitory protein, IκBα.  
This allows translocation of NF-κB/p65 from cytosol to the nucleus [41].   Similarly, our data 
suggest that TNFα induced NF-κB/p65 translocation to the nucleus in all three cell lines.  Hence, 
our data is in agreement with other studies. 
Taken together, PKC-ι activates IKKα/β in constitutive activation of NF-κB in RWPE-1 
and DU-145 cells.  Whereas, TNFα induced NF-κB activation in LNCaP cells is indpendent of 
atypical PKCs.  We further demonstrated that LNCaP cells are sensitive to TNFα treatment and 
undergo apoptosis as observed by cleaved PARP (Asp214), and activation of caspase-7.  These 
data are also in agreement with other reports [25, 34].  TNFα induced death receptors in 
activation of caspase-8 and subsequent activation of caspase-3,-7 and cleaved PARP for 
extrinsic apoptosis [50].  In RWPE-1 and DU-145 cells, TNFα induced very little apoptosis and 
cell survival.  Another key event in NF-κB activation is the translocation of NF-κB/p65 from 
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cytosol to the nucleus [41].  Our results demonstrate that TNFα treatment decreases NF-κB/p65 
in cytosol and increases the NF-κB/p65 in the nucleus in all the three cell lines.  This showed that 
TNFα induces atypical PKCs in activation of the NF-κB pathway (Table 7). 
Although, there are PKC inhibitors such as staurosporine and tamoxifen, they do not 
specifically inhibit PKC-ι [51-52].  Therefore, a putative PKC-ι inhibitor (ICA-1) which targets the 
unique amino acid sequence of the kinase domain 469 - 475 (glutamine-469, isoleucine-470, 
arginine-471, isoleucine-472, proline-473, arginine-474, serine- 475) was used in a kinase assay 
to demonstrate that IKKα/β is the substrate of PKC-ι.  Our data demonstrated that PKC-ι 
phosphorylates IKKα/β when PKC-ι and IKKα/β are co-immunoprecipitated.  However, this 
activity is inhibited by ICA-1, indicating that IKKα/β is the true substrate for PKC-ι.  However, 
there was no significant decrease in the cell proliferation rate in LNCaP and DU-145 cells.  It is 
possible that higher concentration of ICA-1 (greater than 60 μM) will inhibit cell proliferation. 
In addition, we also analyzed the patients’ tissues samples, comparing normal prostate, 
prostate intraepithelial neoplasia and malignant tumor.  Our data demonstrated an 
overexpression of PKC-ι in PIN and malignant tumors compared to normal prostate.  Although 
the samples analyzed are under represented, it is possible that overexpression of PKC-ι in PIN 
may lead to malignant prostate cancer.  Hence, PKC-ι can be a potential biomarker and an 
alternative target for treatment of prostate cancer. 
 
7.6  Conclusion and future directions 
 This study showed that PKC-ι is multifunctional depending on cell types.  In prostate 
cells, PKC-ι associated with Cdk7 for cell proliferation of non-malignant prosate RWPE-1 cells 
and malignant androgen-dependent prostate LNCaP carcinoma cells.   PKC-ι is also required for 
cell survival of androgen-independent prostate DU-145 carcinoma cells.  Inhibition of PKC-ι leads 
to cell apoptosis.  This study also leads to many future challenging areas listed below: 
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1.  Other cdks such as cdk4/6 may associate with PKC-ι in DU-145 cell    proliferation.  
Additionally, cell cycle arrest at G0/G1 in DU-145 cells indicates that other cdks may drive the 
cell cycle and it is not limited to PKC-ι/Cdk7/cdk2 pathway. 
2.  Overexpression of PKC-ι in malignant prostate cells could establish other pathways that are 
yet to be discovered.  Quantification of PKC-ι mRNA in prostate cells will illuminate if PKC-ι 
is transcriptionally regulated. 
3.  LNCaP cells may have a point mutation on PKC-ι that may contribute to no significant 
effects of PKC-ι siRNA on cell proliferation and protein content.   Another synthetic siRNA 
that target different sites on PKC-ι may be a better target for PKC-ι in LNCaP cells.  In 
addition, other PKCs may drive LNCaP cell survival. 
4.  A shift from PKC-ζ in RWPE-1 to PKC-ι in DU-145 may be a possible survival mechanisim 
for androgen-independent prostate cells.  However, activation (i.e phosphorylation) of IKK by 
PKC-ζ remains to be established. 
Therefore, further study on these areas may illuminate the signal transduction pathways involving 
PKC, specific to PKC-ι, in prostate cancer. 
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